

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600

WASHINGTON, D.C. 20005-3934

www.skgf.com

PHONE (202) 371-2600 FACSIMILE (202) 371-2540

ROBERT GREENE STERNE
EDWARD J. KESSLER
JORGE A. GOLDSTEIN
SAMUEL L. FOX
DAVID K.S. CORNWELL
ROBERT W. ESMOND
TRACY-GENE G. DURKIN
MICHELE A. CIMBALA
MICHAEL B. RAY
ROBERT E. SOKOHL
ERIC K. STEFFE
MICHAEL Q. LEE

STEVEN R. LUDWIG
JOHN M. COVERT*
LINDA E. ALCORN
RAZ E. FLESHNER
ROBERT C. MILLONIG
MICHAEL V. MESSINGER
JUDITH U. KIM
TIMOTHY J. SHEA, JR.
DONALD R. MCPHAIL
PATRICK E. GARRETT
STEPHEN G. WHITESIDE
JEFFREY T. HELVEY*

HEIDI L. KRAUS
JEFFREY R. KURIN
RAYMOND MILLIEN
PATRICK D. O'BRIEN
LAWRENCE B. BUGAISKY
CRYSTAL D. SAYLES*
EDWARD W. YEE
ALBERT L. FERRO*
DONALD R. BANOWIT
PETER A. JACKMAN
MOLLY A. MCCALL
TERESA U. MEDLER

JEFFREY S. WEAVER
KRISTIN K. VIDOVICH
KENDRICK P. PATTERSON
DONALD J. FEATHERSTONE
GRANT E. REED
VINCENT L. CAPUANO
JOHN A. HARROUN*
MATTHEW M. CATLETT*
NATHAN K. KELLEY*
ALBERT J. FASULO II*
W. BRIAN EDGE*

KAREN R. MARKOWICZ*
SUZANNE E. ZISKA**
BRIAN J. DEL BUONO**
ANDREA J. KAMAGE**
NANCY J. LEITH**
TARJA H. NAUKKARINEN**

*BAR OTHER THAN D.C.
**REGISTERED PATENT AGENTS

August 10, 2000

WRITER'S DIRECT NUMBER:

(202) 371-2544

INTERNET ADDRESS:

mcimbala@skgf.com

Commissioner for Patents
Washington, D.C. 20231

Box Patent Application

Re: U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)
(Continuation of Appl. No. 09/090,949; Filed: June 5, 1998)
Appl. No. To be assigned; Filed: Herewith
For: **Insulinotropic Hormone GLP-1(7-36) and Uses Thereof**
Inventors: Joel F. HABENER
Our Ref: 0609.1090009/MAC

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. PTO Fee Transmittal (Form PTO/SB/17) (*in duplicate*);
2. PTO Utility Patent Application Transmittal (Form PTO/SB/05);
3. U.S. Utility Patent Application entitled:

Insulinotropic Hormone GLP-1(7-36) and Uses Thereof

and naming as inventor:

Joel F. HABENER

the application consisting of:

- a. A specification containing:
 - i. 59 pages of description prior to the claims;

Commissioner for Patents
August 10, 2000
Page 2


- ii. 4 pages of claims (12 claims);
 - iii. a one (1) page abstract;
 - b. 18 sheets of informal drawings: (Figures 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14A, 14B, 15, and 16);
 - c. A copy of the executed Declaration, as filed in U.S. Appl. No. 07/756,215;
- 4. Preliminary Amendment;
 - 5. Letter to PTO Draftsman: Submission of Formal Drawings (*in duplicate*);
 - 6. 17 sheets of formal drawings: (Figures 1, 2, 3, 4, 5, 6, 7, 7A, 8, 8A, 9, 9A, 10, 10A-C, 11, 12, 13, 14, 14A, 15 and 16), approval of which is respectfully requested;
 - 7. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (*in duplicate*);
 - 8. Two (2) return postcards; and
 - 9. Our check no. 28339 for \$690.00 to cover the filing fee for patent application.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbala
Attorney for Applicant
Registration No. 33,851

MAC/eak
Enclosures



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR § 1.53(b))</i>	Attorney Docket No.	0609.1990009/MAC
	First Inventor or Application Identifier	Joel F. HABENER
	Title	Insulinotropic Hormone GLP-1(7-36) and Uses Thereof
	Express Mail Label No.	

JC511 U.S. Pat. & Tm. Off.
09/09/00
08/10/00

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents.</i>	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification [Total Pages 64] <i>(preferred arrangement set forth below)</i></p> <ul style="list-style-type: none">- Descriptive title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R & D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claim(s)- Abstract of the Disclosure <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 18]</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages 3]</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> <i>[Note Box 5 below]</i></p> <p>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).</p> <p>5. <input checked="" type="checkbox"/> Incorporation By Reference <i>(useable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p> <p>6. <input type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i></p> <p>7. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i></p> <p>a. <input type="checkbox"/> Computer Readable Copy</p> <p>b. <input type="checkbox"/> Paper Copy (identical to computer copy)</p> <p>c. <input type="checkbox"/> Statement verifying identity of above copies</p>	
ACCOMPANYING APPLICATION PARTS	
<p>8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></p> <p>10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i></p> <p>11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>12. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>14. <input type="checkbox"/> *Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired <i>(PTO/SB/09-12)</i></p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>16. <input checked="" type="checkbox"/> Other: 37 C.F.R. § 1.136(a)(3) Authorization</p> <p><input checked="" type="checkbox"/> Other: Letter to PTO Draftsman: Submission of Formal Drawings; and 17 sheets of formal drawings: (Figures 1, 2, 3, 4, 5, 6, 7, 7A, 8, 8A, 9, 9A, 10, 10A-C, 11, 12, 13, 14, 14A, 15 and 16).</p> <p><small>*NOTE FOR ITEMS 1 & 14 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28)</small></p>	
<p>17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:</p> <p><input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-Part (CIP) of prior application No: 09/090,949</p> <p>Prior application information: Examiner N. Minnifield Group/Art Unit: 1645</p>	

18. CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or <input checked="" type="checkbox"/> Correspondence address below					
NAME	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.				
	Attorneys at Law				
ADDRESS	Suite 600, 1100 New York Avenue, N.W.				
CITY	Washington	STATE	DC	ZIP CODE	20005-3934
COUNTRY	USA	TELEPHONE	(202) 371-2600	FAX	(202) 371-2540

NAME (Print/Type)	Michele A. Cimbala	Registration No. (Attorney/Agent)	33,851
SIGNATURE	<i>Michele A. Cimbala</i>	Date	Aug 10, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joel F. HABENER

Appl. No. to be assigned (the accompanying
continuation of 09/090,949)

Filed: Herewith

For: **Insulinotropic Hormone GLP-1 (7-
36) and Uses Thereof**

Art Unit:

Examiner:

Atty. Docket: 0609.1090009/MAC

Preliminary Amendment

Commissioner for Patents
Washington, D.C. 20231

Sir:

In advance of prosecution, please amend the specification and claims as follows. It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

AMENDMENTS

Please enter the following Amendments.

In the Title of the Invention:

Please delete the Title of the Invention and replace therein -- DNA Encoding
Insulinotropic Hormone -- .

In the Specification:

At page 1, line 4, before "continuation-in-part" insert -- continuation of U.S.
Application No. 09/090,949, filed June 5, 1988, which is a continuation of U.S.
Application No. 08/749,762, filed November 20, 1996, Pat. No. U.S. 5,958,909, which is a
continuation of U.S. Application No. 08/156,800, filed November 23, 1993, Pat. No.
5,614,492, which is a continuation of U.S. Application No. 07/756,215, filed September 5,
1991, abandoned, which is a -- .

At page 1, line 5, after "1990", insert -- Pat. No. 5,118,666 -- .

At page 1, line 6, after "1988" insert -- , abandoned, -- .

At page 7, line 13, delete "human,".

At page 7, line 13, delete ", and hamster preproglucagons" and replace therein --
preproglucagon--.

At page 8, line 1, after "Figure 7" insert --and Figure 7A--.

At page 8, line 4, after "Figure 8" insert --and Figure 8A--.

At page 8, line 7, after "Figure 9" insert --and Figure 9A--.

At page 8, line 10, delete "9 and 10" and insert therein --10,10A, 10B and 10C--.

At page 8, line 26, delete "14A" and insert therein --14--.

At page 9, line 1, delete "14B" and insert therein --14A--.

At page 31, line 22, after "37" insert a right parenthesis --) -- .

At page 31, line 22, before "which" insert a left parenthesis -- (-- .

At page 41, line 14, delete "Figure 8 depicts" insert therein --Figures 8 and 8A depict--.

At page 41, line 14, delete "Figure 7. Figure" and insert therein --Figures 7 and 7A. Figures--.

At page 41, line 15, delete "7 shows" and insert therein --7 and 7A show--.

At page 41, line 16, delete "Figures 7 and 8" and insert therein --Figures 7, 7A, 8 and 8A--.

At page 42, line 13, delete "Figures 7 and 8" and insert therein --Figures 7, 7A, 8 and 8A--.

At page 42, line 18, delete "Figures 7 and 8" and insert therein --Figures 7, 7A, 8 and 8A--.

At page 44, line 17, after "7" insert --and 7A--.

At page 46, line 7, after "9" insert --and 9A--.

At page 47, line 14, delete "Figure 10" and insert therein --Figures 10, 10A, 10B and 10C--.

At page 47, line 27, delete "Figure 10(A) and (B)" and insert therein --Figures 10, 10A, 10B and 10C--.

At page 48, line 3, delete "Figure 10(A) and (B)" and insert therein --Figures 10, 10A, 10B and 10C--.

At page 54, line 7, delete "14A" and insert therein --14--.

At page 54, line 11, delete "14B" and insert therein --14A--.

At page 57, line 21, after "(1991)" insert a right parenthesis --) -- .

In the Claims:

Please cancel claims 1-12 without prejudice or disclaimer.

Please add the following new claims:

-- 13. DNA encoding a fragment of GLP-1(1-37) and not GLP-1(1-37), wherein the N-terminus of said fragment is the amino acid at position 7 of said GLP-1(1-37), and wherein said fragment has the amino acid sequence: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly.

14. The DNA of claim 13, wherein said fragment is encoded by the DNA sequence:
CATGCTGAAGGGACCTTTACCA GTGATGTGAGTTCTTACTTGGAGGG
CCAGGCAGCAAAGGAATTCATTGCTTGGCTGGTGAAAGGCCGAGGA. --

Remarks

None of the amendments add new matter. The amendment to the figure legend of Figure 1 in the specification corrects the identification of the sequence. Informal Figure 1 as filed contains the rat sequence. Therefore, the legend to Figure 1 has been amended to reflect this.

The specification has also been amended to reflect the numbering of the panels of the formal Figures, rather than the numbering of the panels on the informal figures that are attached to the specification. *Inter alia*, in the formal drawings, the four panels on Figure 10 were renamed 10, 10A, 10B and 10C. The two panels that were previously Figures 14A and 14B were renamed Figures 14 and 14A to be consistent with the naming of the other formal drawings.

Claims 1-12 have been canceled without prejudice or disclaimer. New claims 13-14 have been added. No new matter has been added. Support for GLP-1(7-37) is found, *inter alia*, at specification page 11 (lines 1-2). Support for DNA encoding a fragment of GLP-1 is found, *inter alia*, at specification page 11 (lines 13-24). Support for a fragment in which the N-terminus begins at position 7 is found, *inter alia* at specification page 11 (lines 1-2). Support for the amino acid and DNA sequence of GLP-1(7-37) is found, *inter alia*, in Figure 1, in positions 7-37 under the line "GLP I," and at specification page 7, lines 12-14.

Conclusion

Based on the amendments and remarks above, Applicant respectfully submits that the application is in condition for allowance. Early notice to this effect is earnestly solicited. If the Examiner believes, for any reason, that personal communication will

TITLE OF THE INVENTION

INSULINOTROPIC HORMONE GLP-1(7-36) AND USES THEREOF

Cross-Reference to Related Applications

5 This application is a continuation-in-part of United States Patent Application No. 07/532,111, filed June 1, 1990, which is a file wrapper continuation of U.S. Application No. 07/148,517, filed January 26, 1988 which is a continuation-in-part of U.S. Application No. 06/859,928, filed on May 5, 1986 and now abandoned.

BACKGROUND OF THE INVENTION

Field of the Invention

10 This invention is directed to the discovery that certain peptide fragments of the prohormone, proglucagon, possess hormonal activities and can be used to stimulate the synthesis and secretion of the hormone, insulin. These peptide fragments are useful in therapy and treatment of maturity onset (type II) diabetes mellitus. This invention is specifically
15 directed to the use of glucagon-like peptide-1(7-36) for the treatment of maturity onset diabetes mellitus, and for use as an insulin secretagogue *per se*.

Description of the Background Art

20 The endocrine secretions of the pancreatic islets are under complex control not only by blood-borne metabolites (glucose, amino acids, catecholamines, etc.), but also by hormonal and local paracrine influences.

The major pancreatic islet hormones (glucagon, insulin, and somatostatin) interact among their specific cell types (A, B, and D cells, respectively) to modulate secretory responses mediated by the metabolites. Although insulin secretion is predominantly controlled by blood levels of glucose, glucagon and somatostatin stimulate and inhibit glucose-mediated insulin secretory responses, respectively. In addition to the proposed interislet paracrine regulation of insulin secretion, there is evidence to support the existence of insulintropic factors in the intestine. This concept originates from the observations that glucose taken orally is a much more potent stimulant of insulin secretion than is a comparable amount of glucose given intravenously.

The human hormone, glucagon, is a 29-amino acid peptide hormone produced in the A-cells of the pancreas. The hormone belongs to a multi-gene family of structurally related peptides that include secretin, gastric inhibitory peptide, vasoactive intestinal peptide, and growth hormone-releasing hormone. These peptides variously regulate carbohydrate metabolism, gastrointestinal mobility, and secretory processes. The principal recognized actions of pancreatic glucagon, however, are to promote hepatic glycogenolysis and gluconeogenesis, resulting in an elevation of blood sugar levels. In this regard, the actions of glucagon are counterregulatory to those of insulin and may contribute to the hyperglycemia that accompanies diabetes mellitus (Dobbs, R., *et al.*, *Science* 187:544-547 (1975)).

In supraphysiologic concentrations, glucagon has been found to be capable of binding to receptors which lie on the surface of insulin-producing cells. Glucagon, when bound to these receptors, stimulates the rapid synthesis of cAMP by these cells. cAMP, in turn, stimulates insulin expression (Korman, L.Y., *et al.*, *Diabetes* 34:717-722 (1985)). Glucose and insulin act to inhibit glucagon synthesis (*Review of Medical Physiology*, Ganong, W.F., 1979, Lang Publications, Los Altos, California (p. 273)).

Thus, the expression of glucagon is down-regulated by insulin, and ultimately by the serum glucose level.

The glucagon gene is initially translated from a 630-base pair precursor to form the polypeptide, proglucagon (Lund, P.K., *et al.*, *Proc. Natl. Acad. Sci., USA* 79:345-349 (1982)). This polypeptide is subsequently processed to form proglucagon. Patzelt, C., *et al.* (*Nature* 282:260-266 (1979)) demonstrated that proglucagon was subsequently cleaved into glucagon and a second polypeptide. Subsequent work by Lund, P.K., *et al.* (*Proc. Natl. Acad. Sci. USA* 79:345-349 (1982)); Lopez, L.C., *et al.* (*Proc. Natl. Acad. Sci. USA* 80:5485-5489 (1983)) and Bell, G.I., *et al.* (*Nature* 302:716-718 (1983)) indicated that the proglucagon molecule was cleaved immediately after lysine-arginine dipeptide residues. Studies of proglucagon produced by channel catfish (*Ictalurus punctata*) indicated that glucagon from this animal was also proteolytically cleaved after adjacent lysine-arginine and arginine-arginine dipeptide residues (Andrews, P.C., *et al.*, *J. Biol. Chem.* 260:3910-3914 (1985)). Lopez, L.C., *et al.* (*Proc. Natl. Acad. Sci. USA* 80:5485-5489 (1983)), and Bell, G.I., *et al.* (*Nature* 302:716-718 (1983)), discovered the mammalian proglucagon was cleaved at lysine-arginine or arginine-arginine dipeptides and demonstrated that the mammalian proglucagon molecule contained three discrete and highly homologous peptide molecules which were designated glucagon, glucagon-like peptide 1 (GLP-1 or GLP-I), and glucagon-like peptide 2 (GLP-2 or GLP-II). Lopez *et al.* (*Proc. Natl. Acad. Sci. USA* 80:5485-5489 (1983)) concluded that GLP-1 was 37 amino acid residues long and that GLP-2 was 34 amino acid residues long. Analogous studies on the structure of rat proglucagon revealed a similar pattern of proteolytic cleavage between adjacent lysine-arginine or arginine-arginine dipeptide residues, resulting in the formation of glucagon, GLP-1, and GLP-2 (Heinrich, G., *et al.*, *Endocrinol.* 115:2176-2181 (1984)). Human

rat, bovine, and hamster sequences of GLP-1 have been found to be identical (Ghiglione, M., *et al.*, *Diabetologia* 27:599-600 (1984)).

The conclusion reached by Lopez *et al.* (*Proc. Natl. Acad. Sci. USA* 80:5485-5489 (1983)) regarding the size of GLP-1 was confirmed by the work of Uttenthal, L.O., *et al.*, (*J. Clin. Endocrinol. Metabol.* 61:472-479 (1985)). Uttenthal *et al.* examined the molecular forms of GLP-1 which were present in the human pancreas. Their research shows that GLP-1 and GLP-2 are present in the pancreas as proteins having 37 and 34 amino acid residues, respectively.

The similarity between GLP-1 and glucagon suggested to early investigators that GLP-1 might have biological activity. Although some investigators found that GLP-1 could induce rat brain cells to synthesize cAMP (Hoosein, N.M., *et al.*, *FEBS Lett.* 178:83-86 (1984)), other investigators failed to identify any physiological role for GLP-1 (Lopez, L.C., *et al.*, *Proc. Natl. Acad. Sci. USA* 80:5485-5489 (1983)). The failure to identify any physiological role for GLP-1 caused some investigators to question whether GLP-1 was in fact a hormone and whether the relatedness between glucagon and GLP-1 might be artifactual (Ghiglione, M., *et al.*, *Diabetologia* 27:599-600 (1984)).

Thus, in conclusion, the prior art reveals an awareness of the processing of a glucagon hormone precursor into a set of peptides sharing extensive homology. It has been widely assumed by those of skill in the art that these highly related glucagon-like peptides would have a biological activity. Nevertheless, extensive investigations designed to elucidate the biological effects of these molecules had been unsuccessful.

SUMMARY OF THE INVENTION

The present invention relates to an insulinotropic hormone comprising a fragment of GLP-1 and derivatives thereof, especially GLP-1(7-36). The invention additionally pertains to the therapeutic uses of such compounds, and especially to the use of GLP-1(7-36) for the treatment of maturity onset diabetes mellitus.

In detail, the invention pertains to a peptide fragment which is insulinotropic and is derivable from a naturally occurring amino acid sequence.

The invention comprises a compound selected from the group consisting of:

(A) GLP-1(7-36) peptide comprising the sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
Val-Ser-Ser-Tyr-Leu-Gly-Gln-Ala-
Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
Lys-Gly-Arg

and

(B) a derivative of such peptide;

wherein the compound is substantially free of natural contaminants, and has an insulinotropic activity which exceeds the insulinotropic activity of GLP-1(1-36) or GLP-1(1-37).

The invention also includes a compound selected from the group consisting of:

(A) GLP-1(7-36) peptide comprising the sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
Lys-Gly-Arg

and

(B) a derivative of such peptide;

wherein the compound is substantially free of natural contaminants, and has an insulintropic activity at a concentration of at least 10^{-10} M.

Of particular interest are GLP-1(7-36) peptides of the following formula:

(1) $H_2N-X-CO-R^1$

wherein R^1 is OH, OM, or $-NR^2R^3$;

M is a pharmaceutically acceptable cation or a lower branched or unbranched alkyl group;

R^2 and R^3 are the same or different and selected from the group consisting of hydrogen and a lower branched or unbranched alkyl group;

X is a GLP-1(7-36) peptide comprising the sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
Lys-Gly-Arg;

NH_2 is the amine group of the amino terminus of X;

and

CO is the carbonyl group of the carboxy terminus of X and where the naturally processed form is arginineamide at position 36 of GLP-1(7-36);

(2) the acid addition salts thereof; and

(3) the protected or partially protected derivatives thereof;

wherein such compound has an insulintropic activity which exceeds the insulintropic activity of GLP-1(1-36) or GLP-1(1-37).

The invention further pertains to a method for enhancing the expression of insulin which comprises providing to a mammalian pancreatic B-type islet cell an effective amount of the insulintropic peptides disclosed above.

The invention further pertains to a method for treating maturity-onset diabetes mellitus which comprises administration of an effective amount of the insulintropic peptides discussed above to a patient in need of such treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the DNA structure and corresponding amino acid sequence of human, rat, and hamster preproglucagons. The preproglucagon precursor is proteolytically cleaved at sites indicated by circles.

Figure 2 shows the ability of the insulintropic peptides glucagon and GLP-1(7-37) to stimulate cAMP formation in the insulinoma line, RIN 1046-38.

Figure 3 shows a comparison of the insulintropic activity of glucagon with that of GLP-1(7-37).

Figure 4 shows a comparison of the insulintropic activities of GLP-1(7-34), GLP-1(7-35), and GLP-1(7-37) using the rat pancreas perfusion technique.

Figure 5 shows the breakdown of GLP-1(1-37) into GLP-1(7-37) under experimental conditions.

Figure 6 shows plasma glucose levels and serum insulin levels in fasting normal subjects during infusion of GLP-1 (7-37).

Figure 7 shows plasma glucose levels and serum insulin levels in fasting maturity onset diabetic subjects during infusion of GLP-1 (7-37). Values are on the basis of relative percentage changes from the baseline.

Figure 8 shows absolute plasma glucose levels and serum insulin levels in fasting maturity onset diabetic subjects during infusion of GLP-1 (7-37).

Figure 9 shows plasma glucose levels and serum insulin levels in maturity onset diabetic subjects during infusion of GLP-1 (7-37) concurrent with a standard meal.

Figures 9 and 10 show the plasma glucose levels and serum insulin levels in maturity onset diabetic subjects during infusion of GLP-1 (7-37) either before or after lowering fasting glucose levels by the administration of overnight insulin infusion.

Figure 11 shows induction of CAT-activity by forskolin (10 μ M), IBMX (0.5 mM), 8-Bromo-cAMP (1 mM) and GLP-1(7-37) (10 nM) in transiently transfected β TC-1 cells, treated for 24 hours. Mean \pm S.D. of 3 or 4 experiments, each performed in triplicate.

Figure 12 shows induction of CAT-activity by increasing concentrations of GLP-1(7-37) in β TC-1 cells transiently transfected for 24 hours with the -410 Ins-CAT expression plasmid. Mean \pm S.D. of 3 or 4 experiments, each performed in triplicate.

Figure 13 shows induction of proinsulin biosynthesis in β TX-1 cells by forskolin (10 μ M), IBMX (0.5 mM) and GLP-1(7-37) (0.1, 10, 1000 nM) during a 6 hour labelling and stimulating period. Mean \pm S.D. of 3 or 4 experiments, each performed in triplicate.

Figure 14A shows increase of proinsulin content in β TC-1 cells after 24 hour treatment with forskolin (10 μ M), IBMX (0.5 mM) and 8-Bromo-cAMP (1 mM). Mean \pm S.D. of 3 experiments, each performed in triplicate.

Figure 14B shows increase of proinsulin content in β TC-1 cells after treatment with GLP-(7-37) (0.1-100 nM). Mean \pm S.D. of 3 experiments, each performed in triplicate.

Figure 15 shows a diagrammatic depiction of the changes in blood glucose and hormone levels during fasting and feeding in animals and humans. It is important to note that glucagon levels rise during fasting in order to stimulate the liver to synthesize glucose to maintain blood glucose levels at 90 mg/dl. During fasting insulin and GLP-1(7-37) levels are low. The secretion of the latter two hormones is stimulated by feeding so that insulin can act on peripheral organs to take up and assimilate glucose and other meal-derived nutrients.

Figure 16 shows a diagram of the insulinotropic actions of GLP-1(7-37). Oral nutrients, such as glucose, absorbed from the intestine during a meal stimulate the intestinal L-cells to secrete GLP-1(7-37) which in turn stimulates the pancreatic B-cells to produce insulin.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

A. GLP-1 and Its Derivatives

The hormone glucagon is known to be synthesized as a high molecular weight precursor molecule which is subsequently proteolytically cleaved into three peptides: glucagon, glucagon-like peptide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2). GLP-1 has 37 amino acids in its unprocessed form. The present invention discloses that the unprocessed GLP-1 is essentially unable to mediate the induction of insulin biosynthesis. The unprocessed GLP-1 peptide is, however, naturally converted to a 31-amino acid long peptide (7-37 peptide) having amino acids 7-37 of GLP-1 ("GLP-1(7-37)"). Applicant has further discovered that GLP-1(7-37) can undergo additional processing by proteolytic

removal of the C-terminal glycine to produce GLP-1(7-36) which also exists predominantly with the C-terminal residue, arginine, in amidated form as arginineamide, GLP-1(7-36) amide. This processing occurs in the the intestine and to a much lesser extent in the pancreas, and results in a polypeptide with the insulinotropic activity of GLP-1(7-37).

A compound is said to have an "insulinotropic activity" if it is able to stimulate, or cause the stimulation of, the synthesis or expression of the hormone insulin. The hormonal activity of GLP-1(7-37) and GLP-1(7-36) appears to be specific for the pancreatic beta (herein "B") cells where it appears to induce the biosynthesis of insulin. The insulinotropic hormone of the invention is useful in the study of the pathogenesis of maturity onset diabetes mellitus, a condition characterized by hyperglycemia in which the dynamics of insulin secretion are abnormal. Moreover, the insulinotropic hormone is useful in the therapy and treatment of this disease, and in the therapy and treatment of hyperglycemia.

Peptide moieties (fragments) chosen from the determined amino acid sequence of human GLP-1 constitute the starting point in the development comprising the present invention. The interchangeable terms "peptide fragment" and "peptide moiety" are meant to include both synthetic and naturally occurring amino acid sequences derivable from a naturally occurring amino acid sequence.

The amino acid sequence for GLP-1 has been reported by several researchers (Lopez, L.C., *et al.*, *Proc. Natl. Acad. Sci., USA* 80:5485-5489 (1983); Bell, G.I., *et al.*, *Nature* 302:716-718 (1983); Heinrich, G., *et al.*, *Endocrinol.* 115:2176-2181 (1984)). The structure of the preproglucagon mRNA and its corresponding amino acid sequence is shown in Figure 1. This figure further displays the proteolytic processing of the precursor gene product, proglucagon, into glucagon and the two glucagon-like peptides. As used herein, the notation of GLP-1(1-37) refers to a GLP-1 polypeptide having all amino acids from 1 (N-terminus) through 37 (C-

terminus). Similarly, GLP-1(7-37) refers to a GLP-1 polypeptide having all amino acids from 7 (N-terminus) through 37 (C-terminus). Similarly, GLP-1(7-36) refers to a GLP-1 polypeptide having all amino acids from number 7 (N-terminus) through number 36 (C-terminus).

5 In one embodiment, GLP-1(7-36) and its peptide fragments are synthesized by conventional means, such as by the well-known solid-phase peptide synthesis described by Merrifield, J.M. (*Chem. Soc.* 85:2149 (1962)), and Stewart and Young (*Solid Phase Peptide Synthesis* (Freeman, San Francisco, 1969), pages 27-66), which are incorporated by reference
10 herein. However, it is also possible to obtain fragments of the proglucagon polypeptide, or of GLP-1, by fragmenting the naturally occurring amino acid sequence, using, for example, a proteolytic enzyme. Further, it is possible to obtain the desired fragments of the proglucagon peptide or of GLP-1 through the use of recombinant DNA technology, as
15 disclosed by Maniatis, T., *et al.*, *Molecular Biology: A Laboratory Manual*, Cold Spring Harbor, New York (1982), which is hereby incorporated by reference.

The present invention includes peptides which are derivable from GLP-1(1-37), such as GLP-1(7-36). A peptide is said to be "derivable from a naturally occurring amino acid sequence" if it can be obtained by
20 fragmenting a naturally occurring sequence, or if it can be synthesized based upon a knowledge of the sequence of the naturally occurring amino acid sequence or of the genetic material (DNA or RNA) which encodes this sequence.

25 Included within the scope of the present invention are those molecules which are said to be "derivatives" of GLP-1(1-37), and especially GLP-1(7-36). Such a "derivative" has the following characteristics: (1) it shares substantial homology with GLP-1(1-37) or a similarly sized fragment of GLP-1(1-37); (2) it is capable of functioning as an
30 insulinotropic hormone and (3) using at least one of the assays provided

herein, the derivative has either (i) an insulintropic activity which exceeds the insulintropic activity of either GLP-1(1-37) or GLP-1(1-36), or, more preferably, (ii) an insulintropic activity which can be detected even when the derivative is present at a concentration of 10^{-10} M, or, most preferably, (iii) an insulintropic activity which can be detected even when the derivative is present at a concentration of 10^{-11} M.

A derivative of GLP-1(1-37) is said to share "substantial homology" with GLP-1(1-37) if the amino acid sequences of the derivative is at least 80%, and more preferably at least 90%, and most preferably at least 95%, the same as that of either GLP-1(1-37) or a fragment of GLP-1(1-37) having the same number of amino acid residues as the derivative.

The derivatives of the present invention include GLP-1(1-37) fragments which, in addition to containing a sequence that is substantially homologous to that of a naturally occurring GLP-1(1-37) peptide may contain one or more additional amino acids at their amino and/or their carboxy termini. Thus, the invention pertains to polypeptide fragments of GLP-1(1-37) that may contain one or more amino acids that may not be present in a naturally occurring GLP-1(1-37) sequence provided that such polypeptides have an insulintropic activity which exceeds that of GLP-1(1-37) or GLP-1(1-36).

Similarly, the invention includes GLP-1(1-37) fragments which, although containing a sequence that is substantially homologous to that of a naturally occurring GLP-1(1-37) peptide may lack one or more additional amino acids at their amino and/or their carboxy termini that are naturally found on a GLP-1(1-37) peptide. Thus, the invention pertains to polypeptide fragments of GLP-1(1-37) that may lack one or more amino acids that are normally present in a naturally occurring GLP-1(1-37) sequence provided that such polypeptides have an insulintropic activity which exceeds that of GLP-1(1-37) or GLP-1(1-36).

The invention also encompasses the obvious or trivial variants of the above-described fragments which have inconsequential amino acid substitutions (and thus have amino acid sequences which differ from that of the natural sequence) provided that such variants have an insulintropic activity which is substantially identical to that of the above-described GLP-1 derivatives. Examples of obvious or trivial substitutions include the substitution of one basic residue for another (i.e. Arg for Lys), the substitution of one hydrophobic residue for another (i.e. Leu for Ile), or the substitution of one aromatic residue for another (i.e. Phe for Tyr), etc.

Examples of derivatives of GLP-1(1-37) that are useful in the methods of the invention include GLP-1(7-37); GLP-1(7-36); GLP-1(7-35); GLP-1(7-34); and the des-Gly³⁷ amidated forms of these molecules. Included as well are the use of additional amino acid residues added to such sequences in order to enhance coupling to carrier protein or amino acid residues added to enhance the insulintropic effect.

As is known in the art, the amino acid residues may be in their protected or unprotected form, using appropriate amino or carboxyl protecting groups. Useful cations are alkali or alkaline earth metallic cations (i.e., Na, K, Li, 1/2Ca, 1/2Ba, etc.) or amine cations (i.e., tetraalkylammonium, trialkylammonium, where alkyl can be C₁-C₁₂).

The variable length peptides may be in the form of the free amines (on the N-terminus), or acid-addition salts thereof. Common acid addition salts are hydrohalic acid salts, i.e., HBr, HI, or, more preferably, HCl.

B. Assays of Insulinotropic Activity

5 The present invention concerns GLP-1(1-37) derivatives which have
an insulinotropic activity that exceeds the insulinotropic activity of either
GLP-1(1-37) or GLP-1(1-36). The insulinotropic property of a compound
may be determined by providing that compound to animal cells, or
injecting that compound into animals and monitoring the release of
immunoreactive insulin (IRI) into the media or circulatory system of the
animal, respectively. The presence of IRI is detected through the use of
a radioimmunoassay which can specifically detect insulin. Although any
radioimmunoassay capable of detecting the presence of IRI may be
employed, it is preferable to use a modification of the assay method of
Albano, J.D.M., *et al.*, (*Acta Endocrinol.* 70:487-509 (1972)). In this
modification, a phosphate/albumin buffer with a pH of 7.4 was employed.
The incubation was prepared with the consecutive condition of 500 μl of
phosphate buffer, 50 μl of perfusate sample or rat insulin standard in
perfusate, 100 μl of anti-insulin antiserum (Wellcome Laboratories;
1:40,000 dilution), and 100 μl of [^{125}I] insulin, giving a total volume of 750
 μl in a 10 x 75-mm disposable glass tube. After incubation for 2-3 days
at 4°C, free insulin was separated from antibody-bound insulin by
charcoal separation. The assay sensitivity was 1-2 $\mu\text{U/ml}$. In order to
measure the release of IRI into the cell culture medium of cells grown in
tissue culture, one preferably incorporates radioactive label into
proinsulin. Although any radioactive label capable of labeling a
polypeptide can be used, it is preferable to use ^3H leucine in order to
obtain labeling of proinsulin. Labeling can be done for any period of time
sufficient to permit the formation of a detectably labeled pool of
proinsulin molecules; however, it is preferable to incubate cells in the
presence of radioactive label for a 60-minute time period. Although any
cell line capable of expressing insulin can be used for determining whether
a compound has an insulinotropic effect, it is preferable to use rat

insulinoma cells, and especially RIN-38 rat insulinoma cells. Such cells can be grown in any suitable medium; however, it is preferable to use DME medium containing 0.1% BSA and 25 mM glucose.

5 The insulintropic property of a compound may also be determined by pancreatic infusion. The *in situ* isolated perfused rat pancreas preparation was a modification of the method of Penhos, J.C., *et al.* (*Diabetes* 18:733-738 (1969)). In accordance with such a method, fasted rats (preferably male Charles River strain albino rats), weighing 350-600 g, are anesthetized with an intraperitoneal injection of Amytal Sodium (Eli Lilly and Co., 160 mg/kg). Renal, adrenal, gastric, and lower colonic blood vessels are ligated. The entire intestine is resected except for about 10 four cm of duodenum and the descending colon and rectum. Therefore, only a small part of the intestine is perfused, thus minimizing possible interference by enteric substances with glucagon-like immunoreactivity. 5 The perfusate is preferably a modified Krebs-Ringer bicarbonate buffer with 4% dextran T70 and 0.2% bovine serum albumin (fraction V), and is preferably bubbled with 95% O₂ and 5% CO₂. A nonpulsatile flow, four-channel roller-bearing pump (Buchler polystatic, Buchler Instruments Division, Nuclear-Chicago Corp.) is preferably used, and a switch from 0 one perfusate source to another is preferably accomplished by switching a three-way stopcock. The manner in which perfusion is performed, modified, and analyzed preferably follows the methods of Weir, G.C., *et al.*, (*J. Clin. Investigat.* 54:1403-1412 (1974)), which is hereby incorporated by reference.

C. Formulations of Insulinotropic Compounds

The insulinotropic peptides (or peptide derivatives) of GLP-1(1-37) and especially GLP-1(7-36), may be used as therapeutic compositions. Such therapeutic compositions may consist solely of the insulinotropic peptides (or peptide derivatives) although, preferably, the compositions will contain the insulinotropic peptides (or derivatives thereof) combined in admixture with a pharmaceutically acceptable carrier vehicle.

Suitable vehicles and their formulation, inclusive of other human proteins, e.g., human serum albumin, are described for example in *Remington's Pharmaceutical Sciences* (16th Ed., A. Oslo Ed. Mack, Easton, PA (1980)). In order to form a pharmaceutically acceptable composition that is suitable for effective administration to a patient in need of such composition, such compositions will contain an effective amount of GLP-1(7-37), or a derivative of GLP-1(7-37) such as GLP-1(7-36), together with a suitable amount of carrier vehicle.

The GLP-1 derivatives of such compounds will preferably have been purified so as to be substantially free of natural contaminants. A material is said to be "substantially free of natural contaminants" if it has been substantially purified from materials with which it is normally and naturally found. Examples of natural contaminants with which GLP-1(7-36) might be associated are: other peptides, carbohydrates, glycosylated peptides, lipids, membranes, etc. A material is also said to be substantially free of natural contaminants if these contaminants are substantially absent from a sample of the material.

Compositions containing GLP-1(7-37) or its derivatives such as GLP-1(7-36) may be administered intravenously, intramuscularly, or subcutaneously at dosages in the range of from about 1 pg/kg to 1,000 μ g/kg body weight, or at concentrations sufficient to produce serum levels of 10^{-10} M to 10^{-11} M, although a lower or higher dosage may be administered.

The required dosage will depend upon the severity of the condition of the patient, for example, the severity of the patient's hyperglycemia, and upon such criteria as the patient's height, weight, sex, age, and medical history. The dose will also depend upon whether the compound of the invention is being administered in a veterinary setting to an animal or to a human patient.

For the purpose of parenteral administration, compositions containing the derivatives of GLP-1(1-37) such as GLP-1(7-36) are preferably dissolved in distilled water and the pH-value is preferably adjusted to about 6 to 8. In order to facilitate the lyophilization process resulting in a suitable product, lactose may be added to the solution. Preferably, the solution is then filtered sterilized, introduced into vials, and lyophilized. In a preferred embodiment, the compound of the invention is administered orally to a patient, at the time of eating or shortly thereafter. The concentration of the GLP-1(1-37) derivatives in these compositions, and especially the concentration of GLP-1(7-36) whether oral or parenteral, may vary from 10^{-12} M to 10^{-5} M.

Additional pharmaceutical methods may be employed to control the duration of action. Controlled release preparations may be achieved by the use of polymers to complex or adsorb the GLP-1(1-37) derivatives and especially GLP-1(7-36). The controlled delivery may be exercised by selecting appropriate macromolecules (for example, polyesters, polyamino acids, polyvinyl pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, and protamine sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled release preparations is to incorporate the derivatives of GLP-1(1-37), and especially GLP-1 (7-36), into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly (lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incor-

porating the GLP-1(1-37) derivatives, and especially GLP-1(7-36), into these polymeric particles, it is possible to entrap these derivatives in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly (methylemethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such teachings are disclosed in *Remington's Pharmaceutical Sciences* (1980).

It is possible to enhance the biological half-life of the GLP-1(1-37) derivatives of the present invention, and especially GLP-1(7-36), and, thus, to increase the retention or stability of the derivatives in a recipient, by bonding such derivatives to one or more chemical "moieties" to thereby produce a compound which can be recognized and processed within a recipient to yield a GLP-1(1-37) derivative, and especially GLP-1(7-36). The "moieties" of such compounds may include one or more lipids, carbohydrates, amino acid residues, etc. A preferred "moiety" is an amino acid residue. The most preferred "moiety" is a peptide. The amino terminal residue of GLP-1(7-36) is a preferred site for the bonding of the "moiety."

An appreciation of this aspect of the present invention can be obtained through a consideration of the natural processing of GLP-1(1-37). GLP-1(1-37) has a biological half-life of 15-20 minutes. A natural cleavage of the amino terminal hexapeptide, GLP-1(1-6), occurs to yield GLP-1(7-37) whose biological half-life is only 3-5 minutes. Thus, the amino terminal hexapeptide, GLP-1(1-6) is a natural "moiety" which when bonded to GLP-1(7-37) increases the biological half-life of GLP-1(7-37). The discovery of such a natural "moiety" is disclosed in Figure 5, and supports the concept that additional or alternative moieties may be employed in the same manner as GLP-1(1-6) to increase the biological

half-life of the GLP-1(1-37) derivatives of the present invention, and especially GLP-1(7-36). Although the present invention does not encompass the use of GLP-1(1-6) as a "moiety," it does include variants of GLP-1(1-6) as well as other peptides of unrelated sequence which are capable of enhancing the half-life of the peptides and peptide derivatives of the present invention.

In summary, insulin secretion from the B cell of the endocrine pancreas is controlled by a complex network of metabolic factors. This network includes such diverse components as glucose, amino acids, catecholamines, and peptides. The decoding of the glucagon gene has uncovered two additional glucagon-like peptides encoded in proglucagon, the polypeptide precursor of glucagon. One of these peptides, glucagon-like peptide-1 (GLP-1) is processed from proglucagon in several forms: 37-amino acids GLP-1(1-37), 31-amino acids GLP-1(7-37), and 30 amino acids GLP-1(7-36). The specific liberation of GLP-1 peptides in the intestine and, to some degree, in the pancreas, suggested to the inventors that the GLP-1 peptides might be components of the entero-insular axis. To resolve this issue, the effects of the GLP-1 peptides on a pancreatic B cell line was studied using a rat perfused pancreas and a cultured rat insulinoma cell-line. These studies have revealed that, in the isolated perfused pancreas, GLP-1(7-37) is a potent stimulator of insulin secretion at concentrations as low as 5×10^{-12} M. At 10^{-11} M, GLP-1(7-36) possesses an insulintropic activity equivalent to GLP-1(7-37) in the perfused pancreas. Insulin release in response to GLP-1(7-37) is highly dependent upon ambient glucose concentration. The longer peptide (GLP-1(1-37)) has no insulin-releasing activity even at concentrations as high as 5×10^{-7} M. Comparison of the insulintropic effects of GLP-1(7-37) and glucagon showed that (in the rat perfused pancreas) GLP-1(7-37) is at least 100 fold more potent in the stimulation of insulin secretion. In the rat insulinoma cell line (RIN 1046-38), GLP-1(7-37), at concentrations of

10⁻¹⁰M to 10⁻¹¹M, increased both the cellular levels of cAMP (5-fold) and the levels of insulin mRNA (3-fold) and also stimulated insulin release. Again the effects of GLP-1(7-37) were more potent than those of glucagon. The magnitude of the insulintropic effects at such low concentrations renders GLP-1(7-37) one of the most potent insulin secretagogues described, including glucagon and gastric inhibitory polypeptide. These results suggest that GLP-1(7-37) and its derivative GLP-1(7-36) may participate in the physiological regulation of pancreatic B cell functions.

Having now fully described the invention, the same will be more readily understood by reference to specific examples which are provided by way of illustration, and are not intended to be limiting of the invention, unless specified.

SPECIFIC EXAMPLES

EXAMPLE 1

Specificity of GLP-1 Peptides

In order to demonstrate that the effects of GLP-1(1-37), GLP-1(1-36) and GLP-1(7-37) were specific for insulin, and were not capable of inducing or provoking non-specific gene expression, the effect of these peptides on the levels of insulin, actin and angiotensinogen mRNAs in rat insulinoma cells were conducted.

Rat insulinoma cells of cell line RIN-38 were derived from a continuous islet cell line, RIN-r, which was established from a transplantable rat islet cell tumor (Gazdar, A.F., *et al.*, *Proc. Natl. Acad. Sci., USA* 77:3519-3523 (1980)). The cells were maintained in DMEM (Gibco) at a glucose concentration of 4,500 mg/L and supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 100 U/ml of penicillin

and 100 $\mu\text{g/ml}$ of streptomycin. Incubations were carried out at 37°C in 95% air:5% CO_2 . Cells grown in the above manner were washed and resuspended in DMEM (Gibco) containing 0.1% bovine serum albumin and 25 mM glucose. Cells were incubated with varying concentrations of insulinotropic peptides (i.e. glucagon, GLP-1(1-37), GLP-1(7-37), or GLP-1(1-36 des-gly-arg amide); Peninsula Laboratories) for six hours, following which the effects of these agents on mRNA expression were determined. In all cases, the concentration of peptides was 10^{-7}M . Incubations were for six hours.

Messenger RNAs specific for insulin, actin, or angiotensinogen were identified by Northern hybridization as follows: cellular RNA was extracted from solid tumors and cells by homogenization in guanidine thiocyanate and sedimentation through a cesium chloride cushion. Poly A⁺ RNA was isolated by oligo dT cellulose chromatography (Aviv, H., *et al.*, *Proc. Natl. Acad. Sci., USA* 69:1408-1412 (1972)). Twenty micrograms of total RNA from each sample were fractionated by size on a 1.4% agarose gel after denaturation in glyoxal, followed by electrotransfer to a nylon membrane (Nytran; Schleicher and Schuell). Blotted membranes were baked for two hours at 80°C under vacuum, prehybridized in 1M NaCl/1% SDS/10% Dextran sulfate at 50°C overnight and hybridized at the same temperature for 24 h after addition of the labeled probes ($3\text{-}5 \times 10^5$ cpm/ml); they were then washed at 55°C twice in 1 x SCC (0.15M NaCl/0.015M Na citrate)/1% SDS, and exposed to X-ray film for varying times at -70°C with an intensifying screen. The relative amounts of the specific mRNA were determined by microdensitometry. The results of this experiment are shown in Table 1.

The glucagon-like peptides increased the levels of insulin mRNA during 24-hr incubations (Table 1). The increase in insulin mRNA levels was consistently greater in response to the shorter, 31-amino acid peptide; 3-fold higher than control values at 24 hr. These stimulatory effects on

insulin mRNA levels and on the release of insulin were observed in the presence of physiologically high (hyperglycemic) (25 mM) and not low (hypoglycemic) (5.5 mM) concentrations of glucose. Evidence that the stimulatory actions of GLP-1 are relatively specific for insulin mRNA was obtained by demonstrating that (i) GLP-1(7-37) had negligible effects on levels of actin and angiotensinogen mRNAs in the insulinoma cell line; (ii) glucagon and GLP-2 had no effects on insulin mRNA levels; and (iii) GLP-1(7-37), when added to the rat islet glucagon-producing cell line 1056A and two pituitary cell lines, one producing prolactin (GH4) and the other corticotropin (AtT-20), had no effects on the levels of glucagon, prolactin, and corticotropin mRNAs, respectively.

GLP-1(7-37) was examined to determine whether it could induce the biosynthesis of mRNA of hormones other than insulin. Thus, GLP-1(7-37) (at a concentration of 10^{-7} M) was added to a rat islet glucagon-producing cell line and two pituitary cell lines (GH4 and AtT-20) which were capable of producing the hormones prolactin and ACTH, respectively, and the amount of hormone specific mRNA produced was determined after 24 hours as described above. GLP-1 peptides had no detectable effect on either the level of prolactin mRNA in GH4 pituitary cells, or in the level of ACTH mRNA in AtT-20 pituitary cells.

Table 1. Densitometric quantitation of effects of glucagon-like peptides on levels of insulin and actin mRNAs in RIN 1046-38 cells

mRNA	Peptide conc., M	Arbitrary densitometric units ¹			
		Control ²	GLP(1-(1-37)	GLP-1-(7-37)	GLP-1-(1-36)-NH ₂
Experiment 1					
Insulin	5 x 10 ⁻⁷	1.28±0.18	1.87±0.35	4.23±0.77 ³	2.78±0.51 ⁴
Actin	5 x 10 ⁻⁷	0.68±0.03	0.48±0.06	0.72±0.16	0.87±0.19
Angioten- sinogen	5 x 10 ⁻⁷	2.67±0.31	2.25±0.20	2.78±0.46	2.56±0.22
Experiment 2					
Insulin	5 x 10 ⁻¹¹	5.90 (6.86,4.99)		7.00(5.58,8.41)	
	5 x 10 ⁻¹⁰			6.70(7.92,5.50)	
	5 x 10 ⁻⁹			8.50(7.59,9.38)	
Actin	5 x 10 ⁻⁸	2.69 (3.23,2.15)		7.90(8.40,7.40)	
	5 x 10 ⁻¹¹			2.11(1.86,2.36)	
	5 x 10 ⁻¹⁰			2.09(2.38,1.79)	
	5 x 10 ⁻⁹			2.46(2.01,2.92)	
	5 x 10 ⁻⁸			1.99(2.24,1.74)	
Experiment 3					
Insulin	5 x 10 ⁻⁷	5.56±0.43		13.87±0.40 ⁵	
Actin	5 x 10 ⁻⁷	3.29±0.08		4.36±0.44	

- 1 Determined by scanning of autoradiograms of RNA blots. Values from experiments 1 and 3 are means ± SEM of triplicate plates of cells; values from experiment 2 are means of duplicates (individual values are given in parenthesis). Statistical significance between control and experimental observations were calculated by Student's unpaired two-tailed t test.
- 2 No peptide added.
- 3 p < 0.02.
- 4 p < 0.05.
- 5 p < 0.001.

EXAMPLE 2

The Effect of GLP-1(7-37) on the Transcription of the Insulin and Other Genes

5 The effect of GLP-1(7-37) on the transcription of the insulin and
actin genes in RIN-38 insulinoma cells was investigated. Gene
transcription rates were determined by quantification of nascent insulin
and beta-actin RNA transcripts in nuclei from control and GLP(7-37)
treated cells. The GLP-1(7-37) concentration was 10^{-7} M. Incubation was
for 4 hours. Nuclear RNA was hybridized to an excess of cloned specific
10 DNA bound to nitrocellulose and the filters were washed as described by
McKnight, G.S., *et al.*, (*J. Biol. Chem.* 254:9050-9058 (1979)). Rat insulin
(Ulrich, A., *et al.*, *Science* 196:113-119 (1977)) and, for control, chicken
beta-actin cDNAs, provided by Dr. D. Cleveland, the Johns Hopkins
University School of Medicine, Baltimore, Maryland, were used.
5 Hybridization efficiency was controlled through the addition of the
hybridization solution of [3 H] UTP insulin cRNA. Experiments were done
in duplicate and values are expressed in ppm/kb of cDNA insert,
corrected for efficiency of hybridization (40-50%). The results of this
experiment revealed that GLP-1(7-37) increased the rate of insulin gene
transcription, but had no detectable effect upon the rate of actin gene
transcription.

EXAMPLE 3

Effect of GLP-1 Derivatives on Cellular cAMP Levels

5 In order to determine whether glucagon-like proteins were
capable of affecting cellular cAMP levels, the effects of GLP-1(7-37) and

GLP-1(1-37) on cAMP levels in RINS-38 insulinoma cells (Expt. I and Expt. II in Table 2, respectively) was determined.

Cells were grown as described in Example 1, in 26 well culture dishes. Varying amounts of glucagon-like peptides were added to culture wells in triplicate. After permitting incubation for 10 minutes, the total cell media was examined for cAMP, and the concentration of cAMP was determined. The results of this experiment are shown in Table 2. Twenty microliters from each culture well was assayed.

Table 2

Peptide Concentration (M)	<u>Expt. I</u>	<u>Expt II</u>
0	140	91
10^{-6}	400	170
10^{-7}	370	120
10^{-8}	494	160
10^{-9}	515	100
10^{-10}	253	90
10^{-11}	533	90

This experiment reveals that GLP-1(7-37) was capable of stimulating cAMP levels even when present at a concentration of 10^{-11} M. The increase in cAMP levels is an indication that GLP-1(7-37) is capable of interacting with cellular receptors. In contrast, neither GLP-1(1-37) nor GLP-2 (GLP-2) exhibited such activity.

A further experiment was performed in order to compare the insulinotropic activities of GLP-1(1-37), GLP-1-(1-36)-NH₂ and GLP-1(7-37) with the insulinotropic activity of glucagon. The procedures for this experiment are the same as those described above. The results of this experiment are shown in Table 3.

At the relatively high concentration of 0.5 μ M, GLP-1(1-37), GLP-1-(1-36)-NH₂, GLP-1(7-37) and glucagon each increased cAMP levels. At 5 nM, GLP-1-(7-37) increased cAMP levels at least 4-fold and was still active at 50 pM. In contrast, the effects of glucagon, GLP-1-(1-37), and GLP-1-(1-36)-NH₂ on the formation of cAMP were negligible at these concentrations.

The ability of the insulinotropic peptides glucagon and GLP-1(7-37) to stimulate cAMP formation in the insulinoma line, RIN 1046-38, was investigated. Insulinotropic activity was monitored as described by Mojsov, S., *et al.*, (*J. Clin. Invest.* 79:616-619 (1987)) and Drucker, D.J., *et al.*, (*Proc. Natl. Acad. Sci.* 84:3434-3438 (1987)), both of which references are incorporated by reference herein. The results of this study are shown in Figure 2, and indicate that GLP-1(7-37) is at least 1000 times more potent than glucagon in inducing cAMP formation.

Table 3. Stimulation of cAMP formation by glucagon and glucagon-like peptides in RIN 1046-38 cells

Exp.	Peptide conc., M	No. of plates	cAMP, fmol* (mean \pm SEM)			
			Control	GLP-1 (7-37)	Glucagon	GLP-1 (1-37) GLP-1 (1-36)-NH ₂
1	No peptide	8	15.4 \pm 0.7*			
	5 x 10 ⁻¹²	5		21.0 \pm 2.0 (a)	18.7 \pm 2.2 (NS)	
	5 x 10 ⁻¹¹	5		23.2 \pm 1.0 (c)	13.2 \pm 1.0 (NS)	
	5 x 10 ⁻¹⁰	5		45.2 \pm 5.9 (c)	16.5 \pm 2.0 (NS)	
2	5 x 10 ⁻⁹	5		148.0 \pm 15.0 (c)	20.1 \pm 2.5 (a)	
	No peptide	4	43.6 \pm 4.1			
	5 x 10 ⁻⁸	4		78.3 \pm 3.1 (c)	44.8 \pm 1.6 (NS)	
	5 x 10 ⁻⁷	4		83.0 \pm 2.1 (c)	93.1 \pm 2.9 (c)	
3	No peptide	5	34.4 \pm 5.2			
	5 x 10 ⁻¹⁰	5		70.8 \pm 5.2 (a)		27.6 \pm 4.6 (NS)
	5 x 10 ⁻⁹	5		134.0 \pm 25.6 (b)		24.3 \pm 1.9 (NS)
	5 x 10 ⁻⁸	5		69.6 \pm 7.0 (b)		30.8 \pm 2.8 (NS)
4	5 x 10 ⁻⁷	5				69.9 \pm 2.6 (c)
		4	41.3 \pm 7.1			70.2 \pm 2.8 (b)

Statistical significance between control (no peptide) and experimental observations (by unpaired two-tailed t test) is as follows: a (P<0.05); b (P<0.01); c (P<0.001); NS, not significant.

* All values are per 1/50th of cell extract per plate.

EXAMPLE 4

Effect of GLP-1 Peptides on Insulin Production

Rat insulinoma cells of cell line RIN-38 were grown in DME medium as described in Example 1. After incubation with 5×10^{-7} M GLP-1(7-37), the concentrations of insulin in the cell culture mediums were determined by radioimmunoassay (as described above). Insulin protein levels were determined after incubation for 1 or 24 hours. The results of this experiment are shown in Table 4.

Table 4

<u>Peptide Added</u>	<u>Insulin Produced (μunits/ml)</u>	
	<u>1 Hour</u>	<u>24 Hours</u>
None	166	2,778
GLP-7 (7-37)	381	5,164

EXAMPLE 5

Pancreatic Perfusion Assay of
Insulinotropic Activity

The pancreas of a live rat was perfused with varying concentrations of GLP-1(1-37) and GLP-1(7-37) as described above. Isolated rat pancreas was prepared according to the method of Weir, G.C., *et al.*, (*J. Clin. Invest.* 54:1403-1412 (1974)), and Penkos, J.C., *et al.* (*Diabetes* 18:733-738 (1969)). The perfusate contained bicarbonate buffer (pH 7.4) and 120 mg/dl glucose, 4% dextran T-70, and 0.2% bovine serum albumin, and was equilibrated with 95% oxygen and 5% carbon dioxide. The first 20 minutes of each perfusion was an equilibrium period. After

5 this initial period, aliquots of perfusate were removed every 2-4 min for
additional 20 min, thus allowing the system to equilibrate for a total of 40
min. The perfusion, including any added insulintropic peptide, was for
6 min and samples were collected at 1-min intervals. When more than
one perfusion was to be performed, the peptide perfusions were followed
by equilibration periods of 20 min, during which four samples 5 min apart
were collected. A second 6-min perfusion followed with the same peptide
as the first perfusion only at 100 times higher concentration of peptide.
Again, samples 1 min apart were collected. The entire perfusion time was
between 70 and 85 min.

5 In each aliquot of perfusate obtained, insulin was determined by
radioimmunoassay. In addition, the efficiency of delivery of the
insulintropic peptide was confirmed by radioimmunoassay of corres-
ponding aliquots of perfusate in which insulin was measured (Mojsov,
S.G., *et al.*, *J. Biol. Chem.* 261:11880-11889 (1986), which reference is
incorporated herein by reference). At one minute intervals, pancreas
effluent insulin levels in picograms/ml were determined by radioimmuno-
assay (as described above). The results of this experiment are shown in
Table 5. Perfusions were done using peptide concentrations of 5×10^{-7} M,
 5×10^{-8} M, and 5×10^{-10} M, 5×10^{-11} M, and 5×10^{-12} M. Peptides were added
after the zero minute effluent value had been determined.

5 GLP-1(1-37) was found to mediate a 3.4-fold increase in effluent
insulin concentrations when perfused into rat pancreas at a concentration
of 5×10^{-7} M; at a concentration of 5×10^{-8} M, this peptide was capable of
mediating only a two-fold increase in serum insulin levels. At a
concentration of 5×10^{-10} M, this peptide was found to mediate only a 20%
increase in serum insulin levels. The observed insulintropic activity of
GLP-1(1-37) in these experiments most probably reflects the presence of
GLP-1(7-37) in the preparations (either through the degradation of GLP-
1(1-37) or due to low level contamination).

GLP-1(7-37) was found to be capable of stimulating a 132-fold increase in insulin levels when provided to rat pancreas at a concentration of $5 \times 10^{-7}M$. At a 10-fold lower concentration (5×10^{-8}), this peptide was capable of directing a 21-fold increase in the effluent concentration of insulin. At a concentration of $5 \times 10^{-10}M$, GLP-1(7-37) was found to be capable of mediating an increase in effluent insulin levels (32-fold). Even at a concentration of $5 \times 10^{-11}M$, GLP-1(7-37) delivered a 15-fold increase in insulin levels whereas GLP-1(1-37) was without effect. $10^{-12}M$ gave an insulinotropic effect in studies described in Weir *et al.* (*Diabetes* 38:338-342 (1989)).

This experiment shows that GLP-1(7-37) is more than 1,000-fold more potent than GLP-1(1-37) in stimulating insulin expression *in vivo*. In addition, the GLP-1 peptides had no effects on the release of the peptide hormone glucagon in these same experiments. Thus, the stimulatory effects of GLP-1 are specific for the beta (B) cells and do not act on pancreatic alpha (A) or delta (D) cells.

The level of GLP-1(1-37) and GLP-1(7-37) in rat portal blood has been measured by radioimmunoassay to be approximately 150 pg/ml (50 pM). The corresponding level in peripheral blood is 50 pg/ml (15 pM). The above-described results were obtained using GLP-1(7-37) at a concentration of 5-50 pM. Thus, these results indicate that GLP-1(7-37) has insulinotropic activity at its physiologic concentration.

Table 5
Insulin Produced (picograms/ml) at
Peptide Concentration

Minutes		$5 \times 10^{-7}M$	$5 \times 10^{-8}M$	$5 \times 10^{-10}M$	$5 \times 10^{-11}M$	$5 \times 10^{-12}M$
GLP-1 (7-37)	0	50	925	205	160	50
	1	6,600	20,700	7,400	2,400	50
	2	4,700	10,500	1,800	1,700	50
	3	1,700	4,000	760	1,900	98
GLP-1 (1-37)	0	1,400	3,000	500	340	50
	1	4,700	6,000	600	180	50
	2	2,900	2,000	640	230	160
	3	2,200	2,000	430	340	50

EXAMPLE 6

Comparison of the Insulinotropic Activities of Glucagon and GLP-1(7-37)

5 Rat pancreas perfusion experiments were conducted as described in Example 5, in order to compare the insulinotropic activity of glucagon with that of GLP-1(7-37). Peptides were perfused (for 5 minutes) at concentrations of 10^{-9} M and 10^{-11} M. As shown in Figure 3, GLP-1(7-37) was found to have more than 100 times the insulinotropic activity of glucagon.

3 This finding is confirmed by the study of the effects of glucagon, GLP-1 (1-37), and GLP-1(7-37) on the cAMP levels in RIN 1046-38 insulinoma cells which is presented in Table 3.

EXAMPLE 7

Insulinotropic Activity of 5 Derivatives of GLP-1(1-37)

3 The insulinotropic activities of GLP-1(7-34) and GLP-1(7-35) were compared to that of GLP-1(7-37) using the rat pancreas perfusion technique described above. Five minute perfusions were employed. As shown in Figure 4 all three of these peptides had detectable insulinotropic activity at a concentration of 10^{-11} M. These results indicate that the tested derivatives of GLP-1(7-37) all have an insulinotropic activity greater than that of GLP-1(1-37, which is inactive at 10^{-11} M).

5 The GLP-1 related peptides: GLP-1(7-36)-NH₂ and GLP-1(7-37) were compared to determine their relative insulinotropic activities. Insulinotropic activity was determined using the pancreatic perfusion assay of Example 6; the perfusion being carried out for 5 minutes. Peptides were present at a concentration of 10^{-11} M. The results of this experiment

are shown in Table 6. These results indicate that both GLP-1(7-37) and GLP-1(7-36)-NH₂ have substantial insulinotropic activity.

TABLE 6

Comparison of the Insulinotropic Activity of
GLP-1(7-37) and GLP-1(7-36)-NH₂

Time (Minutes)	GLP-1(7-36)-NH ₂	GLP-1(7-37)
-1	985 ± 275	1330 ± 280
+1	4550 ± 703	4200 ± 784
+2	3330 ± 637	3280 ± 889
+3	2500 ± 564	2500 ± 505

The effects of GLP-1(7-37) and GLP-1(7-36)-NH₂ on cAMP formation in the insulinoma cell line RIN 1046-38 was determined using the procedure of Example 1. Cells were incubated for 10 minutes in the presence of 0, 10⁻¹¹, 10⁻⁹, or 10⁻⁷M peptides. The results of this experiment are shown in Table 7. These results confirm that both GLP-1(7-37) and GLP-1(7-36)-NH₂ are insulinotropic peptides.

TABLE 7

EFFECTS OF GLP-1(7-37) VERSUS GLP-1(7-36)NH₂
ON cAMP FORMATION IN AN INSULINOMA CELL LINE
(RIN 1046-38 CELLS).

	Peptide N	IBMX (μ M)	Peptide Concentration (M)			
			0	10^{-11}	10^{-9}	10^{-7}
5	None (Control)	8	100	161 \pm 10*		
10	GLP-1(7-37)	4	100		205 \pm 9	202 \pm 17
	GLP-1(7-36)NH ₂	4	100		141 \pm 5	225 \pm 16
	None (Control)	8	500	540 \pm 22		
	GLP-1(7-37)	4	500		501 \pm 49	927 \pm 75
15	GLP-1(7-36)NH ₂	4	500		446 \pm 38	1199 \pm 41
						1676 \pm 113

*All cAMP values are given as/fmoles/10ul of cell extract

EXAMPLE 8

Stability of GLP-1(1-37)

To assess the stability of the 37 amino acid peptide in the experimental conditions, GLP-1(1-37) was incubated for 24 hr in culture medium alone or in medium supplemented with either 0.1% bovine serum albumin or 10% fetal bovine serum. Aliquots of media were analyzed by high-pressure liquid chromatography and radioimmunoassay. Before incubation, no GLP-1(7-37) was detected in the preparation of GLP-1(1-37) (Figure 5). However, after incubation of GLP-1(1-37) in conditioned medium containing 0.1% bovine serum albumin, a small peak of GLP-1(7-37) appeared, indicating that cleavage of GLP-1(1-37) to the smaller, more active GLP-1(7-37) occurs under these experimental conditions.

Insulinotropic Effect of GLP-1 (8-37)

Insulin secretion was studied in the perfused rat pancreas assay described above, with a perfusate glucose level of 6.6 mM. GLP-1 (8-37) was found to have no detectable effect at concentrations at 10^{-11} , 10^{-9} , or 10^{-8} M. A weak insulinotropic activity was detected at 10^{-7} M. At a perfusate glucose level of 16.7 mM, the analog had no effect at 10^{-9} M.

The above described protocol was used to study the effects of the GLP-1(7-37) in the presence or absence of GLP-1 (8-37). GLP-1(7-37), alone at a concentration of 10^{-11} M stimulated mean insulin release of 2.25 ± 0.30 ng/ml. This response was, however, lower (1.30 ± 0.19 ng/ml ($P < 0.025$, $N=7$ for each)) when the same dose was given on a background of the analog. These data indicate that the removal of the 7-histidine from GLP-1(7-37) leads to a loss of agonist function in this system, and

that agonist properties are revealed. Because the agonist activity could only be demonstrated against GLP-1(7-37), and not against glucagon, these two secretagogues appear to act through separate receptors.

Using the above-described perfused rat pancreas system, and a glucose perfusate of 6.6 mM, it was found that 10^{-9} M GLP-1(7-37) was capable of eliciting a biphasic pattern of insulin secretion with an initial spike of release followed by the plateau of sustained release. Furthermore, this response was found to be glucose-dependent; at 10^{-9} M and a perfusate glucose concentration of 2.8 mM, no stimulation of insulin release was seen; at a perfusate glucose concentration of 6.6 mM or 16.7 mM, the mean incremental release above control was 4.7 ± 1.0 or 22.8 ± 4.7 ng/ml, respectively. GLP-1(7-37) was found to be extraordinarily potent. At concentrations of 10^{-12} M it was found to stimulate insulin secretion at a perfusate glucose concentration of 6.6 mM from a base line of 0.8 ± 0.2 ng/ml to a peak of 1.6 ± 0.5 ng/ml ($P < 0.05$). When infused at 10^{-11} M, insulin release was stimulated to a peak of 4.1 ± 1.4 ng/ml and at 10^{-9} M, a peak of 23.1 ± 1.3 ng/ml was obtained. It is not yet known whether this GLP-1 peptide is secreted as the 7-37 form or is the 7-36-amide; both compounds were equally potent secretagogues.

Synthetic glucagon was far less potent with no release found at 10^{-11} M. At 10^{-9} M, however, glucagon was found to produce a peak of 4.5 ± 0.5 ng/ml.

Thus, GLP-1(7-37) and the 7-36-amide are candidates for physiological regulation as an "incretin" or as an endocrine modulator.

EXAMPLE 10

Effects of GLP-1 (8-37) on cAMP Formation in an Insulinoma Cell Line

A comparison of the insulinotropic effects of GLP-1 (8-37), GLP-1(7-37) and glucagon on cAMP formation by the insulinoma cell line RIN 1046-38 was determined using the procedure of Example 1. The results of this experiment is shown in Table 8. These results show that GLP-1 (8-37) has an insulinotropic activity which is comparable to that of glucagon, and that GLP-1(7-37) has an insulinotropic activity which is more than 100 times greater than that of either GLP-1 (8-37) or glucagon.

TABLE 8

Effects of GLP-1 (8-37) versus GLP-1(7-37)
and Glucagon on cAMP Formation in
an Insulinoma Cell Line (RIN 1046-38 cells)

Peptide	Concentration (M)	cAMP Formation*
None		27 ± 2
GLP-1 (8-37)	10 ⁻⁸	28 ± 0.8**
	10 ⁻⁷	24 ± 2
	10 ⁻⁶	31 ± 3
	10 ⁻⁵	77 ± 11
GLP-1(7-37)	10 ⁻⁸	128 ± 10
Glucagon	10 ⁻⁶	92 ± 9

*All cAMP levels are given as f-mole/5 ul of cell extract/15 min exposure to peptide

**Means ± S.E.M. (n = 4)

EXAMPLE 11

The experiments and results presented below pertain to the administration of GLP-1(7-37) to non-insulin dependent (type II) diabetic and non-diabetic subjects. Non-insulin dependent (type II) diabetes

(NIDDM) is also known as "maturity-onset diabetes." Two types of experiments were performed. In the first set of experiments, the effect of GLP-1(7-37) infusion on glucose and insulin levels of fasting individuals (diabetic and non-diabetic) was determined. In the second set of experiments, the effect of GLP-1(7-37) infusion on glucose and insulin levels at mealtimes was evaluated.

For all experiments, GLP-1(7-37) was synthesized by the stepwise solid-phase method of Merrifield, R.B. (*J. Am. Chem. Soc.* 95:2149-2154 (1963)). The peptide was purified by preparative reverse-phase C-18 chromatography on a Water Delta-Prep apparatus. The purified peptide was shown to be homogenous by amino acid analysis, preview-sequence analysis, and high performance liquid chromatography (HPLC) on reverse-phase C-18 in two different solvent systems, ion-exchange DEAE-52 columns and mass spectral analysis.

For all experiments, plasma glucose levels were determined with a hexokinase assay, GLP-1(7-37) and insulin (Soeldner *et al.*, *Diabetes* 14:771-777 (1965)) was measured with radioimmunoassays in plasma and serum samples, respectively. Samples for GLP-1(7-37) were collected into EDTA containing tubes with 1,000 IU of aprotinin (trasylol) per ml of blood. The tubes were kept at 4°C and plasma was separated within 5 minutes of collection. Plasmas and sera were kept frozen at -20°C until they were assayed. The radioimmunoassay for GLP-1(7-37) was performed in 0.1 M sodium borate buffer, pH 8.2, containing 5% bovine serum albumin, 50 mM EDTA, 0.1 M benzamidine and 0.2% merthiolate. Plasma samples (0.05 ml), antiserum (0.4 ml at a final dilution of 1:10,000) and radioiodinated GLP-1(7-37) (0.6 ml, 8,000-8,500 cpm) in a total volume of 1.2 ml were incubated for four days at 4°C. Separation of antibody-bound from free peptide was accomplished with dextran-coated charcoal. This assay is identical to the assay previously reported by Mojsov *et al.* (*J. Biol. Chem.* 261:11880-11889 (1986)) and has a

detection limit of 5 pg/ml. It has less than 0.001% cross-reactivity with glucagon, GLP-1, GLP-2, and insulin. The inter- and intra-assay coefficients of variation for the GLP-1(7-37) and insulin assays were less than 10% and 5% respectively. Hemoglobin A_{1c} was measured with an HPLC method with inter- and intra-assay coefficients of variation <2.5% and a non-diabetic range of 3.8-6.4% as described by Nathan, D.M. (*Clin. Chem.* 27:1261-1263 (1981)). Statistical analyses were performed with students paired and unpaired 2-tailed t-test, as indicated, using the Clinfo system.

In order to determine the therapeutic utility of GLP-1(7-37) in the treatment of hyperglycemia and maturity onset diabetes, four healthy non-diabetic and seven type II diabetic males and two type II diabetic females between 18 and 65 years of age and with no known history of other diseases were recruited. The non-diabetic subjects had no history of glucose intolerance or obesity and no family history of diabetes. The only selection criteria for the type II diabetic subjects were that they were in generally good health, had never received insulin therapy and had been treated with diet alone. The baseline characteristics of the subjects are shown in Table 9.

Table 9
Characteristics of the Non-diabetic and type II
Diabetic Subjects Studied

Subject	Non-diabetic (n=4)	Diabetic (n=9)
Age (years)	16.5 ± 3.0	54.4 ± 7.8
Ideal body weight (%)	99.0 ± 1.5	128 ± 23.0
Duration diabetes (years)	---	4.8 ± 5.1
Hemoglobin A _{1c} (%)	4.88 ± 0.4	7.67 ± 1.2
All values expressed as mean ± S.D.		

Subjects were requested to fast for at least 10 hours prior to the morning of testing. Intravenous lines were placed in each arm, one for withdrawal of blood specimens and one for the administration of GLP-1(7-37). An infusion of normal saline was used to keep the intravenous line open. After 45 minutes of saline infusion during which blood specimens were obtained every 15 minutes, either GLP-1(7-37) or continued saline was infused (Harvard Infusion Pump 22, Harvard Apparatus, Inc., So. Natick, MA). GLP-1(7-37) was infused at 1.25, 2.5, 5.0 or 20 ng/kg/min for 30 minutes on separate mornings. Blood samples were obtained every 5 minutes during the 30-minute infusion, at 2-minute intervals for 10 minutes after the cessation of the GLP-1(7-37) infusion to allow determination of the peptide disappearance rates, and at 15- to 30-minute intervals for another 90 to 120 minutes.

Subjects were admitted on separate mornings for the infusion of either GLP-1(7-37) or saline. Neither the subject nor the investigators knew whether placebo or test substance was being administered, and the order of administration was randomized. During the infusions, subjects were asked to perform mental arithmetic in order to test for symptoms of

hypoglycemia (low blood sugar). In addition, blood pressures and pulse rates were measured every 15 minutes. Studies were performed with the subjects continuing to fast during the entire study period (in fasting studies, non-diabetic subjects n=3, diabetic subjects n=5) or with a standard breakfast meal (450 calories, 50% carbohydrate, 30% fat and 20% protein) consumed during the first 15-20 minutes of the GLP infusion ("meal studies" in non-diabetic subjects n=1, diabetic subjects n=5). All meal studies were performed with a 5 ng/kg/min GLP-1(7-37) infusion.

1) Results of Experiments with Fasting Individuals

a) Normal Subjects

Figure 6 shows that the infusion of GLP-1(7-37) in normal, non-diabetic fasting human subjects stimulates insulin secretion and lowers plasma glucose levels. GLP-1(7-37) or saline was infused into three subjects at a rate of 5.0 ng/kg/min for 30 minutes after an overnight fast. Levels of insulin and GLP-1(7-37) were measured by radioimmunoassays. Measurements obtained for the GLP-1(7-37) and saline placebo infusions are shown in closed and open symbols, respectively. Values shown are means \pm SEMs.

The fasted non-diabetic subjects were found to respond to GLP-1(7-37) (5 ng/kg/min) with an approximately 3-fold increase in insulin levels from 6.5 ± 1.6 μ U/ml at time 0 to a mean peak value of 17.7 ± 8.6 μ U/ml at 15 minutes after the beginning of the peptide infusion (Figure 6). Insulin levels peaked midway during the infusion (at 15 min) and began to decline during the infusion despite stable elevated GLP-1(7-37) levels, but concurrent with a fall in plasma glucose. Glucose concentrations declined from a mean baseline value of 90 ± 6 mg/dL

(5.0±0.33 mmol/L) to a nadir of 68±6 mg/dL (3.78±0.33 mmol/L) 34 minutes after the infusion began. One subject had symptoms consistent with mild hypoglycemia concurrent with a plasma glucose level of 62 mg/dL (3.44 mmol/L). GLP-1(7-37) levels rose by approximately 2.5-fold during the infusion. The insulin levels begin to fall after 15-20 minutes of the GLP-1(7-37) infusion, concomitant with the fall in plasma glucose levels. One explanation is that the fall in insulin levels is a consequence of the direct dependency of the insulinotropic actions of GLP-1(7-37) on the blood glucose levels (Weir *et al.*, *Diabetes* 38:338-342 (1989)).

b. Diabetic Subjects

The fasted maturity onset diabetic subjects were found to respond to GLP-1(7-37) infusions (5 ng/kg/min) with relative insulin responses that were similar to those of the fasted non-diabetic subjects (Figure 6). Figure 8 depicts the absolute values of the data shown in Figure 7. Figure 7 shows relative percentage changes from the baseline (beginning of the infusion, time 0). Figures 7 and 8 show that infusion of GLP-1(7-37) (5 ng/kg/min) in three fasting non-insulin dependent diabetic subjects stimulates insulin secretion (bottom) and lowers plasma glucose levels (top). Results are expressed as change from baseline (plasma glucose 194±20 and 178±0.9 and 14.6±3.4 µU/ml at t=0 during placebo and GLP-1(7-37) infusion, respectively). Symbols are the same as in Figure 6. The stimulation of insulin secretion is maintained throughout the 30 minute infusion of GLP-1(7-37). * denotes p<0.5 GLP-1(7-37) vs. placebo.

Table 10 shows the changes in insulin levels in both sets of subjects. (In Table 10, all values are expressed as mean ± S.D.; * denotes peak insulin during 30 min infusion minus baseline (t=0) value; + denotes area under curve of insulin values between 0 and 30 minutes minus baseline

insulin; # denotes only one NIDDM subject; @ denotes two NIDDM subjects; ++ denotes $p < .05$ GLP-1(7-37) vs. saline infusion.) The basal, pre-GLP-1(7-37) infusion insulin levels of the maturity onset diabetic subjects were approximately 3-fold greater than were the levels of the non-diabetic subjects. GLP-1(7-37) infusions resulted in a graded insulin response with a similar 3-fold increase from pre-infusion levels as was observed for the non-diabetic subjects given the 5 ng/kg/min infusion. The insulin peak levels and insulin area under the curve increased by ten-fold compared with the values obtained during the placebo infusion of saline (Table 10). Unlike the responses in the non-diabetic subjects, the diabetic subjects experienced a more prolonged and variable period of increased insulin levels lasting until the termination of the GLP-1(7-37) infusion (Figures 7 and 8). Glucose levels of the diabetic subjects were in the clearly diabetic range at the beginning of the GLP-1(7-37) infusion (range 176-286 mg/dL, 9.78-15.9 mmol/L) and decreased progressively (range of 10% to 31% decrease from baseline) during the GLP-1(7-37) infusion and for a period of 30-90 minutes following termination of the infusion (Figures 7 and 8). GLP-1(7-37) infusions produced a graded increase in GLP-1(7-37) levels with a 1.5-3 fold increase during 2.5 to 5 ng/kg/min infusion rates, respectively, similar to the results obtained in the non-diabetic controls.

Table 10
Changes in Serum Insulin during Infusion of GLP-1(7-37) or Saline
in Non-diabetic and NIDDM Subjects

	GLP-1(7-37) Infusion (ng/kg/min)				
	0 (Saline)	1.25	2.5	5.0	20.0
Non-diabetic Subjects (n=3) Peak insulin (uU/mL)*	0 0	---	---	11.8 ± 6.7 219.0 ± 76.0	---
NIDDM Subjects Fasting studies (n=3) Peak insulin (uU/mL) Area under curve (uU/mL 30 min)	5.0 ± 2.6 123.0 ± 100	6.2# 123.0#	24 ± 15++ 545 ± 422++	43 ± 21++ 924 ± 571++	51 ± 18a 628 ± 317
Meal Studies (n=5) Peak insulin (uU/mL) Area under curve (uU/mL 30min)	10.0 ± 12.0 141.0 ± 147			45 ± 6++ 752 ± 535++	

All values expressed as mean ± S.D.

- * Peak insulin during 30 min infusion minus baseline (t=0) value
- + Area under curve of insulin values between 0 and 30 minutes minus baseline insulin
- # Only one NIDDM subject
- a Two NIDDM subjects
- ++ p<.05 GLP-1(7-37) vs. saline infusion

Although the purpose of these studies was not to generate detailed and rigorous dose-response curves, it is apparent from the results that in the diabetic subjects, in whom several doses of GLP-1(7-37) were tested, there is a dose-related response for insulin secretion (Table 10) and to a modest extent for lowering of glucose levels. Responses were somewhat heterogeneous in that in one subject insulin secretion appeared to be maximal at the lowest dose of GLP-1(7-37) administered (2.5 ng/mg/kg).

The achievement of near-steady state levels of GLP-1(7-37) during the 30-minute infusions permitted an estimation of the metabolic clearance rates (MCR) of the peptide (Table 11). The data for non-diabetic and diabetic subjects alike are in reasonably good agreement (MCRs of 14.6 ± 1.7 and 12.4 ± 2.9 ml/min/kg, respectively). Half-times of disappearance of the GLP-1(7-37) for non-diabetic subjects (9.7 ± 1.9) and diabetic subjects (11.9 ± 4.4 min) calculated from the equilibrium kinetics of the infusions were approximately 50% longer than the values of 6 minutes measured directly from the peptide decay curves following termination of the infusions (Figures 6 and 7). No differences were

observed in the MCRs or $T_{1/2}$, amongst the non-diabetic and diabetic subjects.

Table 11
GLP-1(7-37) Metabolic Clearance Rates in
Non-diabetic and Diabetic Subjects

Subjects	#	Weight (kg)	Infusion Rate (ng/kg/min)	Plasma** IR GLP-1 (ng/ml)	MCR (ml/min/kg)	T 1/2*** (min)
Non-diabetic Subjects	1	68	5	0.31	16.1	8.7
	2	82	5	0.43	11.6	11.9
	3	70	5	0.31	16.1	8.5
	MEAN (SD)				14.6 (2.6)	9.7 (1.9)
Maturity Onset Diabetic Subjects	1	72	2.5	0.19	13.1	10.5
			5.0	0.44	11.4	12.1
			20.0	3.3	6.1	23.1
	2	70	2.5	0.18	13.9	9.1
			5.0	0.49	10.2	13.5
			20.0	1.5	13.3	10.3
	3	81	1.25	0.09	14.7	9.4
			2.5	0.16	15.6	8.9
			5.0	0.37	13.6	10.2
	Mean (SD)				12.4 (2.9)	11.9 (4.4)

- * GLP-1(7-37) infused for 30 minutes.
 ** Difference between baseline and equilibrium values (achieved by 15-20 min of infusion)
 *** Calculated from steady-state equation assuming $dH/dt=0$ and volume of distribution is the ECF (of body weight)

2) Results of Meal Studies.

Figure 9 shows the results of infusions of GLP-1(7-37) (5 ng/kg/min) in five non-insulin dependent diabetic subjects concurrent with a standard meal (closed squares and circles) or infusion of a saline placebo (open squares and circles). Glucose results are in the top figure

and insulin results are in the bottom figure. Symbols are the same as in Figure 6. * denotes $p < 0.05$ or GLP-1(7-37) vs. placebo.

These studies showed uniform results among the five subjects. During GLP-1(7-37) infusion (5 ng/kg/min), the expected postprandial rise in plasma glucose was essentially eliminated for the first 60 minutes after the meal in association with a significant, three-fold increase in insulin levels compared with the placebo infusion (Figure 9, Table 10). Mean plasma glucose fell from 174 ± 44 mg/dL at the start of the meal and GLP-1(7-37) infusion to a nadir of 147 ± 52 mg/dL 45 minutes later. With placebo infusion, plasma glucose increased from 164 ± 25 mg/dL to 238 ± 46 mg/dL during the same time period. The glucose level increased after cessation of the GLP-1(7-37) infusion and reached the same levels as with the placebo infusion by 120 minutes after the meal. Mean insulin level peaked 10 minutes after beginning the GLP-1(7-37) infusion and decreased during the remainder of the infusion, albeit remaining two-fold over baseline, similar to the pattern seen in the fasting studies in the non-diabetic subjects.

The single meal study in a non-diabetic was similar to the studies in the diabetic subjects showing a two-fold increase in insulin during GLP-1(7-37) infusion.

These results establish that GLP-1(7-37) stimulates insulin secretion in human subjects, including subjects with type II diabetes mellitus (maturity onset diabetes). The insulinotropic actions of GLP-1(7-37) appeared to be near maximal at doses of 2.5 to 5.0 ng/kg/min given for 30 minutes, infusion rates that raise the blood level of immunoreactive GLP-1(7-37) to approximately 1.5 to 2.5-fold of background levels. In the one subject to whom an infusion of 1.25 ng/kg/min was administered, a 1.5-fold rise in serum insulin levels was seen in circumstances in which no rise in circulating GLP-1(7-37) was detectable.

The meal studies demonstrate a similar insulinotropic effect of GLP-1(7-37) as seen in the fasting studies. Insulin levels associated with

GLP-1(7-37) infusion led to a decrease in glucose levels post-prandially. Thus, in humans as well as in rats, GLP-1(7-37) is a physiologically potent stimulator of insulin secretion.

3) Glucose Dependence Studies

5 In the perfused rat pancreas and hamster and mouse insulinoma cell lines, the insulintropic actions of GLP-1(7-37) are glucose-dependent, that is, the insulintropic actions are augmented by higher ambient glucose concentrations and attenuated by lower glucose concentrations. To determine whether, in the pancreas of human
10 subjects, the insulintropic actions of GLP-1(7-37) are also glucose dependent, the relative insulintropic responses of GLP-1(7-37) were studied in two subjects with type II diabetes mellitus before and after lowering their fasting glucose levels by the administration of an overnight insulin infusion. Figure 10 shows the results of this study and the
15 demonstration that the insulintropic action of GLP-1(7-37) is glucose-dependent.

Two fasting subjects with type II diabetes mellitus were administered a 30 minute infusion of GLP-1(7-37) at a dose of 5 ng/kg/min according to the precise protocol described for Figure 7. During
20 the night following the initial GLP-1(7-37) infusion (before insulin, open circles), the subjects were administered insulin to lower fasting plasma glucose levels. The following morning the insulin infusions were discontinued and additional GLP-1(7-37) infusion tests were carried out (after insulin, closed circles). The overnight insulin infusion resulted in a
25 lowering of the fasting glucose levels in the two subjects from 236 mg/dL and 201 mg/dL (control day) to 124 and 133 mg/dL, respectively (after overnight insulin infusion (Figure 10(A) and (B))). The peak increments in insulin were 34 and 15 μ U/ml in the two subjects in the first control GLP-1(7-37) infusion study. However, after the insulin infusion resulted

in lower fasting glucose levels, GLP-1(7-37) infusion resulted in blunted GLP-1(7-37)-stimulated peak insulin increments of 20 and 8 μ U/ml/30 min in the two subjects, respectively (Figure 10(A) and (B)). Thus, the results of these studies in two human subjects agree with the previously demonstrated direct glucose-dependency of the insulinotropic actions of GLP-1(7-37) in rat and mouse pancreatic beta cells. In addition, these results further support the utility of treating hyperglycemia, or hyperglycemic states, with GLP-1(7-37) administration.

In summary, the (1) demonstration that GLP-1(7-37) stimulated insulin secretion from the pancreas in subjects with type II diabetes mellitus, coupled with (2) the results of experiments presented in the examples that demonstrate the *in vitro* insulinotropic properties all GLP-1(7-37) and GLP-1(7-36), support a conclusion that GLP-1(7-36) in addition to GLP-1(7-37), has utility as a therapeutic agent for the treatment of maturity onset diabetes.

It is desirable to treat patients with type II diabetes mellitus with an agent that stimulates endogenous insulin secretion rather than administering insulin by subcutaneous injections because the endogenous insulin is delivered directly to the liver through the portal blood flow rather than from the systemic circulation. Furthermore, *in vivo*, GLP-1 appears to be produced almost entirely in the intestinal neuroendocrine L-cells and released into the bloodstream in response to the ingestion of oral nutrients. Thus, GLP-1(7-37) and its derivatives, unlike the sulfonylureas, is a naturally occurring substance that could be exploited as an effective medication for the treatment of type II diabetes mellitus. It is a significant advantage of the invention that, because of the postulated direct dependency of the insulinotropic actions of GLP-1(7-37) on the glucose levels demonstrated *in vitro* (Weir *et al.*, *Diabetes* 38:338-342 (1989)), hypoglycemia, as occurs in the treatment of patients with subcutaneously administered insulin or oral sulfonylureas, predictably would not be a side-effect of treatment with GLP-1(7-37).

The results presented above demonstrate that GLP-1(7-37) stimulates insulin secretion and lowers plasma glucose levels, in these patients, at infusion rates of peptide (1-5 ng/kg/min over 30 min) that raise plasma levels of immunoreactive GLP-1(7-37) by only 0.5 to 2-fold. The results indicate that insulinotropic activity was demonstrable with a 30-minute infusion in both the fasting state and when administered concurrent with a meal. In diabetic subjects, GLP-1(7-37) infusion (compared with placebo) was found to lead to a three-fold increase in insulin levels and completely eliminated the post-prandial rise in plasma glucose for 60 min after beginning the meal.

These studies present evidence of the potent insulinotropic effects of GLP-1(7-37) in patients with noninsulin-dependent (type II) diabetes mellitus as well as in non-diabetic subjects. These findings of potent insulinotropic actions of GLP-1(7-37) in patients with type II diabetes in both the fasting and prandial states indicate that GLP-1(7-37) and its derivatives GLP-1(7-35) and GLP-1(7-34) have therapeutic utility as an effective medication for the treatment of patients with hyperglycemia or type II diabetes mellitus (maturity onset diabetes).

EXAMPLE 12

Insulinotropic Hormone GLP-1(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma Cells

During the intestinal processing of proglucagon, two bioactive forms of GLP-1 are synthesized (Mojsov *et al.*, *J. Biol. Chem.* 265:8001-8008 (1990)): GLP-1(7-37) and GLP-1(7-36)amide; it has been discovered that both peptides possess identical insulin releasing effects. Since the N-terminal part of the molecule is responsible for receptor binding and activation the biological importance of the existence of these forms of GLP-1 is unknown. Therefore, with regard to function, at the pancreatic B-cell, GLP-1(7-37) and GLP-1(7-36)amide can be used synonymously.

This study characterizes GLP-1(7-37) as a stimulator of proinsulin gene transcription and biosynthesis in the glucose-responsive mouse insulinoma cell line β TC-1. These studies lead to a concept that GLP-1(7-37) represents not only a physiologically important insulin secretagogue but also replenishes insulin in the β -cell by increasing proinsulin gene transcription and biosynthesis.

To study the mechanism by which GLP-1(7-37) might act on proinsulin gene transcription, gel mobility shift assays were performed using synthetic oligonucleotides containing the sequence for the CRE (cyclic AMP response element) of the rat insulin I gene, nuclear extracts from β TC-1 cells and bacterial CREB (cyclic AMP response element binding protein) 327/341.

I. Methods

A. Cell Culture

β TC-1 cells (Efrat *et al.*, *Proc. Natl. Acad. Sci. (USA)* 85:9037-9041 (1988)) were grown in a humidified atmosphere at 37°C in RPMI 1640 medium supplemented with 10% (vol/vol) fetal bovine serum, 5% (vol/vol) horse serum, 100 U/ml penicillin and 100 μ g/ml streptomycin. Media were changed after three days and cells were split 1:3 after six days.

B. Cell Transfections and CAT-assay

Cells of two 80-90% confluent 150 mm culture plates were trypsinized and transfected in solution in one tube with 15 μ g of indicator plasmid using the DEAE-dextran method. The plasmid contained 410 bp of the rat insulin I gene promoter fused to the transcriptional reporter gene encoding the bacterial enzyme chloramphenicol-acetyltransferase (CAT). The plasmid was constructed by linking the Pvu II/RsaI fragment (-140 to +65) of the rat insulin I gene into the vector PO-CAT.

Subsequently cells were plated into 18 wells of six well plates. This procedure provides parallel experimental and control cells from the same transfection at identical conditions (the same media changes, harvest at identical time points, with or without treatments with GLP-1(7-37) or signal transducing agents). The cell number of each well was controlled by determination of protein concentration in the cell lysate and did not vary by more than 10%. Thereby, differences in transfection deficiencies reflected in CAT activities were normalized against protein concentrations as well as the respective control experiments. After transfection cells were incubated in RPMI 1640 supplemented with 0.1% human serum albumin and 0.1% bacitracin. Treatment of cells was begun immediately after transfection and the respective agents were added from 100x stock solutions [(GLP-1(7-37); IBMX; 8-Bromo-cAMP; or 1000x stock solution (forskolin). After 24 hours incubation under these conditions cells were harvested in 1.5 ml buffer containing 150 mM NaCl, 1 mM EDTA and 40 mM Tris/Cl pH 7.4 and lysed in 70 μ l 1M Tris/Cl pH 7.4 by three freeze-thaw cycles. CAT activities were determined in 55 μ l of cell lysates; the assay mixture was 70 μ l 1M Tris/Cl pH 7.4, 55 μ l cell lysate in 250 mM Tris/Cl pH 7.4, 20 μ l 4 mM acetyl-CoA in water, 0.5 μ l 14 C chloramphenicol (0.05 μ Ci) and incubations were carried out for 120 minutes. After extraction with ethylacetate (1 ml) acetylated and non-acetylated 14 C-chloramphenicol were separated by thin-layer chromatography (chloroform:methanol 9:1), identified by autoradiography and the respective spots were scraped from the plates and radioactivity was counted in a scintillation counter.

C. Studies of Proinsulin Biosynthesis

β TC-1 cells were plated into 35 mm plates and grown for two days to reach 80-90% confluency. During a 6 hour labeling period cells were incubated in 1 ml RPMI 1640 supplemented with 0.1% human serum

albumin, 0.1% bacitracin and 50 μCi [^3H]leucine. Forskolin, IBMX, 8-Bromo-cAMP and GLP-1(7-37) were added from stock solutions as described (see "cell transfection"). Cells were harvested in PBS and lysed by three freeze-thaw cycles. Immunoreactive proinsulin was precipitated with an antiserum raised in rabbits against pork insulin that was coupled to a 10% suspension of bacterial lysates (Saureus) containing protein A. Radioactivity contained in the resulting pellets was counted using a liquid scintillation counter. Incorporation of [^3H]leucine into total protein was measured in trichloroacetic acid precipitates of the cells. None of the agents tested had any effects on [^3H]leucine incorporation into TCA precipitable proteins. Data are expressed as fold-induction of proinsulin biosynthesis above those in the control experiments (no treatment).

D. Determination of Cellular Insulin Content

Two days before the experiment commenced, cells were plated into 35 mm plates. Media were changed to RPMI 1640 supplemented with 0.1% human serum albumin and 0.1% bacitracin. Forskolin, IBMX, 8-Bromo-cAMP and GLP-1(7-37) were added as described (see "cell transfections"). After incubation for 24 hours under these conditions, cells were washed three times with PBS and harvested in 1.5 ml buffer containing 150 mM NaCl, 1 mM EDTA and 40 mM Tris/Cl pH 7.4 and resuspended in 200 μl PBS. Fifty μl of this cell suspension were resuspended in 1 ml 1M acetic acid and extracted for 16 hours at 4°C. Aliquots (2 and 20 μl) were lyophilized and reconstituted in insulin-RIA buffer. The cell number of each plate was controlled by determination of total protein in the initial cell lysate. Protein concentrations did not vary more than 10%. Insulin was measured with a radioimmunoassay system using an antiserum raised in rabbits against pork insulin and pork insulin as the standard. Free and bound hormones were separated by dextran-coated charcoal (Albano *et al.*, *Acta Endocrinol. (Copenh.)* 70:487-494

(1972)). Data are presented as fold-increase of insulin content per well above the control experiments (no treatment).

II. Results

A. Transfection Experiments

5 β TC-1 cells were transiently transfected with a plasmid containing 410 bp of the rat insulin I gene promoter fused to the transcriptional reporter gene encoding the bacterial enzyme chloramphenicol-acetyltransferase. Cells were treated for 24 hours with forskolin, IBMX, 8-Bromo-cAMP and GLP-1(7-37) as indicated and CAT-activities in the
10 cell lysates were determined. GLP-1(7-37) (10 nM) induced a 2.3 ± 0.23 fold increase of CAT activity compared to control cells (no treatment) (Figure 11). Forskolin (10 μ M), IBMX (0.5 mM) and 8-Bromo-cAMP (1 mM) increased CAT activity 3.3 ± 0.57 , 2.6 ± 0.16 and 2.1 ± 0.8 fold, respectively.

15 In the next set of experiments transiently transfected β TC-1 cells were treated with increasing concentrations of GLP-1(7-37) (100 pM-1 μ M) (Figure 12). The GLP-1(7-37) effect was maximal at 10 nM (2.1 ± 0.3 fold induction) and in cells treated with 0.1 and 1 μ M GLP-1(7-37) CAT-activity was clearly lower compared to cells exposed to
20 10 nM GLP-1(7-37).

B. Proinsulin Biosynthesis Experiments

During the 6 hours of labeling of β TC-1 cells with [3 H]leucine, forskolin (10 μ M) and IBMX (0.5 mM) induced a 1.53 ± 0.06 fold increase of proinsulin biosynthesis (Figure 13). Comparable to the
25 transfection experiments, GLP-1(7-37) stimulated proinsulin biosynthesis concentration-dependently with a maximal action at 10 nM (1.56 ± 0.11 -fold increase). At 1 μ M GLP-1(7-37), 3 H-incorporation into

proinsulin was lower (1.26 ± 0.13 fold increase) compared to the experiments with 10 nM GLP-1(7-37) (Figure 13).

C. Effect of GLP-1(7-37) on Insulin Content in β TC-1 cells

Treatment of β TC-1 cells for 24 hours with forskolin (10 μ M), IBMX (0.5 mM), and 8-Bromo-cAMP (1 mM), induced an increase of total cellular insulin content (1.49 ± 0.18 , 1.30 ± 0.12 and 1.36 ± 0.28 fold-increase) (Figure 14A). The increase of total cellular insulin content induced by GLP-1(7-37) was maximal at 10 nM GLP-1(7-37) (1.52 ± 0.20 fold increase) and cells treated with 0.1 and 1 μ M GLP-1(7-37) contained less insulin compared to cells exposed to 10 nM GLP-1(7-37) (1.33 ± 0.11 and 1.26 ± 0.21 fold increase) (Figure 14B).

D. Binding of Nuclear Factors and CREB 327/341 to the Insulin Gene CRE

Gel-shift analysis was done in order to study nuclear proteins from β TC-1 cells binding to the rat insulin I gene. Cyclic response element nuclear extracts from these cells were prepared, incubated with a labeled double-stranded synthetic oligonucleotide containing the sequence of 195 to -170 of the rat insulin I gene promoter and bacterially expressed CREB 327/341. The DNA/protein complexes were separated by electrophoresis. Sample 1 contained free probe. Samples 2-4 contained CREB 327/341 and a 1000, 100, and 10-fold molar excess of unlabeled oligonucleotide. Sample 5 contained CREB 327/341, but no specific competitor was added. Two proteins with different affinities to the insulin gene CRE could be identified. Binding of the protein with the lower electrophoretic mobility to this gene fragment was partially competed by the addition of a 10-fold molar excess of unlabeled oligonucleotide and 100 and 1000-fold molar excess abolished the binding completely. Binding

of the protein with the higher electrophoretic mobility was partially competed only by a 1000-fold molar excess of unlabeled oligonucleotide. Because it seemed possible that one of the detected insulin CRE binding proteins represents CREB, the possibility was investigated whether bacterial CREB 327/341 binds *in vitro* to this gene fragment.

Gel-shift analysis of nuclear extracts from β TC-1 cells was done using a labeled double-stranded synthetic oligonucleotide containing the sequence of 195 to -170 of the rat insulin I gene promoter. Sample 1: free probe; Sample 2: nuclear extracts, but no specific competitor added; Samples 3-5: nuclear extracts, and a 10-, 100- and 1000-fold molar excess of unlabeled oligonucleotide added. The results showed that this bacterial expressed protein (CREB 327/341) binds *in vitro* specifically to the insulin gene CRE. The binding was competed concentration-dependently and comparable to the protein with the lower electrophoretic mobility detected in β TC-1 cell nuclear extracts. Even a 10-fold molar excess of unlabeled oligonucleotide inhibited the binding of this protein to the labeled probe.

E. Detection of CREB 327/341 in Nuclear Extracts of β TC-12 Cells

To test the possibility of whether β TC-1 cells express CREB 327/341-like proteins, nuclear proteins of these cells were separated by SDS polyacrylamide gel electrophoresis and blotted on nitrocellulose. Using the Western blot technique and a specific antiserum directed against CREB 327/341, a single band was detected representing a protein of approximately 40 kD that ran in parallel with bacterially-expressed CREB 327/341.

III. Discussion

5 The above study of Example 12 demonstrates that GLP-1(7-37) is
a potent stimulator of proinsulin gene transcription and proinsulin
biosynthesis that results in an elevated cellular content of insulin after
treatment of insulinoma β TC-1 cells with GLP-1(7-37). Therefore, GLP-
1(7-37) is not only a powerful insulin secretagogue but it also acts as an
"insulinotropic" substance that restores the intracellular insulin pool via an
increase of proinsulin gene transcription and biosynthesis. These
properties discriminate GLP-1(7-37) from (1) other substances such as the
sulphonylureas that act as potent insulin secretagogues but not as
stimulators of proinsulin biosynthesis (Morris *et al.*, *Biochim. Biophys. Acta*
208:404-413 (1970); Schatz *et al.*, *Acta Endocrinol. (Copenh)* 26:237-240
(1972)), and (2) from other structurally related polypeptide members of
the glucagon-related superfamily that do not share this insulinotropic
property. The findings lead to a wider concept of the entero-insular axis
in which GLP-1(7-37) releases insulin directly after GLP-1(7-37) is
secreted from the intestine in response to a meal (Figure 15). By
elevating intracellular cAMP levels of B cells, transcriptional and probably
translational mediators are activated, resulting in an increase in proinsulin
biosynthesis during interprandial periods when the insulin secretory
demand is low, thereby preparing the B cell for the next meal.

The actions of GLP-1(7-37) on proinsulin gene transcription were
concentration-dependent with a maximum at 10 nmol/l. This observation
correlates with earlier findings demonstrating a maximal stimulation of
insulin release and cAMP generation from perfused and incubated
insulinoma cells in the presence of 10 nM GLP-1(7-37) (Fehmann *et al.*,
FEBS Let. 279:335-340 (1991); Fehmann *et al.*, *Endocrinology* 128 (in
press) (1991)). The inhibition of insulin release and cAMP production at
concentrations above 10 nmol/l GLP-1(7-37) was shown to be due to a
rapid and reversible homologous desensitization of the GLP-1(7-37)

receptor (Fehmann *et al.*, *Endocrinology* 128 (in press) (1991)). This phenomenon might also account for the decrease in proinsulin gene transcription and proinsulin biosynthesis in the presence of 100 and 1000 nmol/l GLP-1(7-37). Other G-protein coupled receptors (e.g., β -adrenergic receptor, M1-muscarinergic receptor) were shown to be down-regulated by longer exposure of cells with high concentrations of ligands (Wang *et al.*, *FEBS-Lett.* 276:185-188 (1990); Hausdorff *et al.*, *Faseb J.* 4:2881-2889 (1990)). Therefore, a ligand-induced down-regulation of the GLP-1(7-37) receptor might also contribute to the decreased proinsulin gene transcription. Because this latter phenomenon appears to be regulated at least in part by the mRNA levels (Wang *et al.*, *FEBS-Lett.* 276:185-188 (1990); Hausdorff *et al.*, *Faseb J.* 4:2881-2889 (1990)), equivalent studies with the GLP-1(7-37) receptor can be performed after cloning and isolation of the cDNA encoding the GLP-1(7-37) receptor.

Of interest in this context is the recent finding of elevated GLP-1(7-37) levels in plasmas of patients with non-insulin dependent diabetes mellitus (NIDDM). Although not intending to be bound by this interpretation, it is possible that a homologous desensitization on the GLP-1(7-37) receptor might contribute to the impaired insulin secretion in this disorder (Orskov *et al.*, *J. Clin. Invest.* 87:415-423 (1991). In addition, it is possible that proinsulin gene transcription and proinsulin biosynthesis also might be decreased in patients with NIDDM. However, *in vitro* studies with insulinoma cells may not accurately reflect the *in vivo* pathophysiological situation in man.

The data are in agreement with studies demonstrating increased levels of proinsulin mRNA after treatment of islets or cultured B-cells with agents that elevate intracellular cAMP levels (Drucker *et al.*, *Proc. Natl. Acad. Sci. (USA)* 84:3434-3438 (1987); Niesen *et al.*, *J. Biol. Chem.* 260:11585-11589 (1985); Welsh *et al.*, *J. Biol. Chem.* 260:13590-13594 (1985); Hammonds *et al.*, *FEBS-Lett.* 213:149-154 (1987); Hammonds *et*

al., *FEBS-Lett.* 223:131-137 (1987); Philippe *et al.*, *J. Biol. Chem.* 265:1465-1469 (1990); German *et al.*, *J. Biol. Chem.* 265:22063-22066 (1990)). Results obtained in the transient transfection experiments support the concept that GLP-1(7-37) acts via cAMP-mediated proinsulin gene transcription (Philippe *et al.*, *J. Biol. Chem.* 265:1465-1469 (1990)). In addition, it was shown previously that both GIP and the cAMP analog dibutyryl cAMP stimulate proinsulin biosynthesis in pancreatic and cultured insulinoma (RINm5F) cells, respectively (Schäfer *et al.*, *Acta Endocrinol. (Copenh)* 91:493-500 (1979); Dobs *et al.*, *In Vitro Cell Dev. Biol.* 25:112-114 (1989)).

A recent report using HIT-T15 cells characterized a functionally active cAMP responsive element (CRE) in the promoter region (-184 to -176) of the rat insulin I gene (Philippe *et al.*, *J. Biol. Chem.* 265:1465-1469 (1990)). Functional data, performed in another insulinoma cell line (TC-1 cells), confirm these and previous results obtained in studies with isolated islets from different species that demonstrate elevated levels of proinsulin mRNA after treatment with substances that increase intracellular cAMP levels (Drucker *et al.*, *Proc. Natl. Acad. Sci. (USA)* 84:3434-3438 (1987); Niesen *et al.*, *J. Biol. Chem.* 260:11585-11589 (1985); Welsh *et al.*, *J. Biol. Chem.* 260:13590-13594 (1985); Hammonds *et al.*, *FEBS-Lett.* 213:149-154 (1987); Hammonds *et al.*, *FEBS-Lett.* 223:131-137 (1987); Philippe *et al.*, *J. Biol. Chem.* 265:1465-1469 (1990); German *et al.*, *J. Biol. Chem.* 265:22063-22066 (1990)). Although not intending to be bound by this interpretation, these data suggest a model for a mechanism for the action of GLP1(7-37) on proinsulin gene transcription: GLP-1(7-37) receptor binding activates the adenylate cyclase system that triggers an increased activity of protein kinase A that phosphorylates and activates CREB 327/341 (Lee *et al.*, *EMBO J.* 9:4455-4465 (1990); Habener *et al.*, *Mol. Endocrinol.* 4:1087-1094 (1990)).

In conclusion, this study extends the knowledge of the entero-insular ("incretin") axis by demonstrating that GLP-1(7-37) stimulates

proinsulin gene expression and proinsulin biosynthesis (Figure 16). Although blood glucose and other nutrients, e.g. amino acids, are the major stimulants of insulin secretion, the secretory actions of the nutrients are markedly augmented by GLP-1(7-37) through its actions on specific receptors located on the B-cells. In contrast to the stimulation of insulin and GLP-1(7-37), the rise in blood glucose and nutrients following a meal suppresses the secretion of glucagon from the A-cells. Recently, it was discovered that the D-cells that produce somatostatin also have GLP-1(7-37) receptors raising the possibility of yet additional control mechanisms by which somatostatin may exert a paracrine negative feedback to suppress glucagon-secretion further and to dampen the insulinotropic actions of GLP-1(7-37).

GLP-1(7-37) represents not only an important mediator of postprandial insulin release, but also restores the insulin pool of the pancreatic B-cell. Therefore, GLP-1(7-37) is a real physiological "insulinotropin" and not only an "insulin-secretagogue." The action of GLP-1(7-37) on proinsulin gene transcription is likely to be mediated at least in part by the cAMP-responsive transcriptional transactivator protein CREB 327/341.

Having now fully described this invention, it will be apparent to one of ordinary skill in the art that the same may be carried out with minor modifications which do not affect the content or spirit thereof.

WHAT IS CLAIMED IS:

1. A method for treating type II diabetes mellitus in an individual in need of such treatment, said method comprising providing an amount of an insulintropic molecule sufficient to treat said diabetes; wherein said molecule is selected from the group consisting of:

(A) a peptide having the amino acid sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
Lys-Gly-Arg;

and

(B) a derivative of said peptide (A), wherein said derivative is selected from the group consisting of:

- (1) a pharmaceutically acceptable acid addition salt of said peptide;
- (2) a pharmaceutically acceptable carboxylate salt of said peptide;
- (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and,
- (4) a pharmaceutically acceptable amide of said peptide;

wherein said molecule has an insulintropic activity which exceeds the insulintropic activity of GLP-1(1-36) or GLP-1(1-37); said molecule combined in admixture with a suitable pharmaceutically acceptable carrier.

2. The method of treating type II diabetes mellitus of claim 1 wherein said insulintropic molecule is a derivative (B) of said peptide (A).

3. The method of treating type II diabetes mellitus of claim 1 wherein said insulintropic molecule is peptide (A).

4. The method of treating type II diabetes mellitus of claim 1, wherein said derivative (B) of said peptide (A) is selected from the group consisting of a lower alkyl amide and a lower alkyl diamide.

5. A method for enhancing the expression of insulin which comprises providing to a mammalian pancreatic B-type islet cell an effective amount of the insulintropic molecule selected from the group consisting of:

(A) a peptide having the amino acid sequence:

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
Lys-Gly-Arg;

and

(B) a derivative of said peptide (A), wherein said derivative is selected from the group consisting of:

- (1) a pharmaceutically acceptable acid addition salt of said peptide;
- (2) a pharmaceutically acceptable carboxylate salt of said peptide;
- (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and,
- (4) a pharmaceutically acceptable amide of said peptide;

wherein said molecule has an insulintropic activity which exceeds the insulintropic activity of GLP-1(1-36) or GLP-1(1-37); said molecule combined in admixture with a suitable pharmaceutically acceptable carrier.

6. The method of enhancing the expression of insulin of claim 5 wherein said insulintropic molecule is said derivative (B) of said peptide (A).

7. The method of enhancing the expression of insulin of claim 5 wherein said insulintropic molecule is peptide (A).

8. The method of enhancing the expression of insulin of claim 5, wherein said derivative (B) of said peptide (A) is selected from the group consisting of a lower alkyl amide and a lower alkyl diamide.

9. A method for simulating insulin secretion from the pancreas in a patient in a hyperglycemic state, said method comprising providing an amount of an insulintropic molecule sufficient to stimulate insulin secretion in said patient;

wherein said molecule is selected from the group consisting of:

(A) a peptide having the amino acid sequence:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-
Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-
Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-
Lys-Gly-Arg;

and

(B) a derivative of said peptide (A), wherein said derivative is selected from the group consisting of:

- (1) a pharmaceutically acceptable acid addition salt of said peptide;
- (2) a pharmaceutically acceptable carboxylate salt of said peptide;
- (3) a pharmaceutically acceptable lower alkyl ester of said peptide; and,
- (4) a pharmaceutically acceptable amide of said peptide;

wherein said molecule has an insulintropic activity which exceeds the insulintropic activity of GLP-1(1-36) or GLP-1(1-37); said molecule combined in admixture with a suitable pharmaceutically acceptable carrier.

5 10. The method for stimulating insulin secretion of claim 9 wherein said insulintropic molecule is said derivative (B) of said peptide (A).

11. The method for stimulating insulin secretion of claim 9 wherein said insulintropic molecule is peptide (A).

10 12. The method for stimulating insulin secretion of claim 9 wherein said derivative (B) of said peptide (A) is selected from the group consisting of a lower alkyl amide and a lower alkyl diamide.

5

A137-12.WP5

	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Joel F. Habener

Appl. No. To be assigned (the
accompanying continuation of 09/090,949)

Filed: Herewith

For: **Insulinotropic Hormone GLP-1(7-
36) Thereof**

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 0609.1090009/MAC

Letter to PTO Draftsman: Submission of Formal Drawings

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith are 17 sheets of formal drawings with Figures 1, 2, 3, 4, 5, 6, 7, 7A, 8, 8A, 9, 9A, 10, 10A-C, 11, 12, 13, 14, 14A, 15 and 16, corresponding to the informal drawings submitted with the above-captioned application. The application number, group art unit and attorney docket number appear on the back of each sheet. Acknowledgment of the receipt, approval, and entry of these formal drawing(s) into this application is respectfully requested.

It is not believed that an extension of time is required, other than any already provided herewith. However, if an extension of time is needed to prevent abandonment of the application, then such extension of time is hereby petitioned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this Letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbalà
Attorney for Applicant
Registration No. 33,851

Date: Aug. 10, 2000
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

GLPII

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn Leu Ala Thr Arg	
CAT GCT GAT GGA TCC TTC TCT GAT GAG ATG AAC ACG ATT CTC GAT AAC CTT GCC ACC AGA	555

Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr Asp Lys Lys End	
GAC TTC ATC AAC TGG CTG ATT CAA ACC AAG ATC ACT GAC AAG AAA TAG gaatatttcaccatt	618

cacaaccatcttcacaacatctcctgccagtcactgggatgtacatttgagagcatatccgaagctatactgcttgc 697

atgcggacgaatacatctcccttagcgttggtgaacccaaagggtgtaaatggaataaaagttttccagggtgtgat 776

aaagtaacaaactttacagtatgaaaatgctggattctcaaatgtctcctcgttttgaaagtaccgccctgagattact 855

tttctgtgtataaaattgtaaaattatcgcagtcacgacacctggattacaacaacagagacatggtaacctggttaacc 933

gtagtgggtgaacctggaaagagaacttcttccttgaaccctttgtcataaatgcgctcagctttccaatgtatcaagaat 1012

agatttaataataatctcat_{3'} 1024

FIG. 1 CONT.




FIG.2




FIG. 3




FIG. 4




FIG. 5

Figure 1 is a line graph showing the effects of GLP-I(7-37) infusion on normal subjects (n=3). The x-axis represents Time (minutes) from -60 to 60. The left y-axis has two scales: Plasma Glucose (mg/dL) (■, □) and GLP-1 (pg/ml) $\times 10^{-2}$ (▲, △). The right y-axis represents Serum Insulin (μ U/ml) (●, ○). A dashed vertical line at 0 minutes indicates the start of the GLP-I(7-37) infusion, which is shown as a shaded box from 0 to 30 minutes. Plasma Glucose (filled squares) starts at approximately 98 mg/dL and decreases to about 62 mg/dL during the infusion, then returns to baseline. GLP-1 (filled triangles) starts at approximately 1.8 $\times 10^{-2}$ pg/ml and increases to a peak of about 5.2 $\times 10^{-2}$ pg/ml during the infusion, then returns to baseline. Serum Insulin (filled circles) starts at approximately 5 μ U/ml and increases to a peak of about 18 μ U/ml during the infusion, then returns to baseline. The open symbols represent baseline or control values.




FIG.7




FIG.7A




FIG.8




FIG.8A




FIG.9




FIG.9A

SUBJECT R.W.

BEFORE INSULIN

AFTER INSULIN

GLP-1(7-37)

PLASMA GLUCOSE (mg/dl)

TIME (MINUTES)

Time (minutes)	Plasma Glucose (mg/dl) - Before Insulin	Plasma Glucose (mg/dl) - After Insulin
-60	258	135
-45	248	133
-30	246	133
-15	243	133
0	235	138
15	232	135
30	212	128
45	205	125
60	192	123
90	183	128
120	175	131

SUBJECT R.W.

BEFORE INSULIN

AFTER INSULIN

GLP-1(7-37)

SERUM INSULIN (μ U/ml)

TIME (MINUTES)

Time (minutes)	Before Insulin (μ U/ml)	After Insulin, GLP-1(7-37) (-) (μ U/ml)	After Insulin, GLP-1(7-37) (+) (μ U/ml)
-60	9	6	6
-45	7	7	7
-30	9	9	9
-15	8	7	7
0	8	7	7
5	12	8	8
10	29	16	16
15	35	25	25
20	42	27	27
25	36	27	27
30	38	23	23
35	42	26	23
40	35	23	23
45	24	12	12
50	16	8	8
65	13	8	8
95	13	8	8
120	11	7	7

FIG. 10A

SUBJECT E.C.

BEFORE INSULIN

AFTER INSULIN

GLP-1(7-37)

PLASMA GLUCOSE (mg/dl)

TIME (MINUTES)

Time (minutes)	Plasma Glucose (mg/dl) - Before Insulin	Plasma Glucose (mg/dl) - After Insulin
-60	210	100
-45	205	100
-30	205	105
-15	200	115
0	200	125
15	195	130
30	185	115
45	175	110
60	178	112
90	165	115
120	160	108

SUBJECT E.C.

SERUM INSULIN (μ U/ml)

BEFORE INSULIN

AFTER INSULIN

GLP-1(7-37)

TIME (MINUTES)

Time (minutes)	Before Insulin (μ U/ml)	After Insulin (μ U/ml)
-60	6.0	5.0
-45	6.5	5.0
-30	6.5	4.0
-15	5.5	3.0
0	6.5	4.0
5	9.0	5.5
10	17.0	7.0
15	19.0	8.5
20	19.5	13.5
25	20.0	12.5
30	21.5	12.0
35	18.0	8.5
40	15.5	11.5
45	8.0	6.5
60	6.5	5.5
90	6.5	5.0
120	6.0	5.5

FIG. 10C




FIG.11




FIG.12




FIG.13




FIG.14




FIG.14A




FIG.15




FIG. 16

Declaration for Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

INSULINOTROPIC HORMONE GLP-1 (7-36) AND USES THEREOF

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on September 5, 1991 as
Application Serial No. 07/756,215
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
_____ (Number)	_____ (Country)	_____ (Day Month Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day Month Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day Month Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

<u>07/532,111</u> (Application Serial No.)	<u>June 1, 1990</u> (Filing Date)	<u>Pending</u> (Status)
<u>07/148,517</u> <u>06/859,928</u> (Application Serial No.)	<u>January 26, 1988</u> <u>May 5, 1986</u> (Filing Date)	<u>(ABANDONED)</u> <u>(ABANDONED)</u> (patented, pending, abandoned)


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	Joel F. Habener	
Inventor's signature	<i>Joel F. Habener</i>	<i>October 10, 1991</i> ^{Date}
Residence	217 PLYMOUTH ROAD, NEWTON HIGHLANDS, MA 02161	
Citizenship	USA	
Post Office Address	SAME AS ABOVE	
Full name of second joint inventor, if any		
Second Inventor's signature		Date
Residence		
Citizenship		
Post Office Address		

Full name of third inventor, if any	
Third Inventor's signature	Date
Residence	
Citizenship	
Post Office Address	
Full name of fourth inventor, if any	
Fourth Inventor's signature	Date
Residence	
Citizenship	
Post Office Address	
Full name of fifth inventor, if any	
Fifth Inventor's signature	Date
Residence	
Citizenship	
Post Office Address	
Full name of sixth inventor, if any	
Sixth Inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

(Supply similar information and signature for subsequent joint inventors, if any)

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) 1 of Drawing were not present:
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present:
for scanning. (Document title)

☐ Scanned copy is best available.